var title_f40_44_41664="Lumbar hernia inf triangle";
var content_f40_44_41664=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F71107&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F71107&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lumbar hernia through the inferior triangle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 290px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Eisenberg, RL. Clinical Imaging: An Atlas of Differential Diagnosis, Fourth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_44_41664=[""].join("\n");
var outline_f40_44_41664=null;
var title_f40_44_41665="Basic case 10 with answer";
var content_f40_44_41665=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F62199&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F62199&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Atrial flutter and incomplete RBBB",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 450px; height: 99px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Atrial flutter with a variable degree of atrioventricular block and incomplete right bundle branch block. The latter is characterized by the rSR' pattern in lead V1 without a prolonged QRS duration.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ary Goldberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_44_41665=[""].join("\n");
var outline_f40_44_41665=null;
var title_f40_44_41666="Contents: Endocrine surgery";
var content_f40_44_41666=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?5/48/5902\">",
"       General Surgery",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Endocrine surgery",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Endocrine surgery",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Adrenal",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/46/28391\">",
"           Adrenal steroid biosynthesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/38/20073\">",
"           Adrenalectomy: Minimally invasive surgery (MIS) and traditional open procedures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/13/5338\">",
"           Approach to the patient with hypertension and hypokalemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/55/26489\">",
"           Causes and pathophysiology of Cushing's syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/0/40969\">",
"           Causes of primary adrenal insufficiency (Addison's disease)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/50/3880\">",
"           Causes of secondary and tertiary adrenal insufficiency in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/20/2376\">",
"           Chapter 6C: Aldosterone",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/1/37911\">",
"           Clinical features of primary aldosteronism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/5/22618\">",
"           Clinical features, diagnosis, and management of von Hippel-Lindau disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/0/33800\">",
"           Clinical manifestations of adrenal insufficiency in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/14/23786\">",
"           Clinical presentation and diagnosis of pheochromocytoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/33/12826\">",
"           Clinical presentation and evaluation of adrenocortical tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/48/22282\">",
"           Epidemiology and clinical manifestations of Cushing's syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/31/31225\">",
"           Establishing the cause of Cushing's syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/25/21913\">",
"           Establishing the diagnosis of Cushing's syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/17/25876\">",
"           Hyponatremia and hyperkalemia in adrenal insufficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/1/9240\">",
"           Metabolism of adrenal steroids",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/63/1016\">",
"           Overview of the treatment of Cushing's syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/54/21351\">",
"           Pheochromocytoma in genetic disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/26/17834\">",
"           Primary therapy of Cushing's disease: Transsphenoidal surgery and pituitary irradiation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/47/34550\">",
"           Surgical anatomy of the adrenal glands",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/8/18569\">",
"           The adrenal incidentaloma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/31/38388\">",
"           Thyroid gland dysfunction in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/37/34390\">",
"           Treatment of adrenocortical adenomas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/51/40762\">",
"           Treatment of adrenocortical carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/54/32616\">",
"           Treatment of pheochromocytoma in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/16/40199\">",
"           Treatment of primary aldosteronism",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Bone",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/56/40842\">",
"           Bisphosphonates in the management of osteoporosis in postmenopausal women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/18/38184\">",
"           Causes of vitamin D deficiency and resistance",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/55/11128\">",
"           Diagnosis and evaluation of osteoporosis in postmenopausal women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/42/37545\">",
"           Evaluation and management of aromatase inhibitor-induced bone loss",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/15/9462\">",
"           Metabolism of vitamin D",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/37/42583\">",
"           Overview of dual-energy x-ray absorptiometry",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/52/39754\">",
"           Overview of the management of osteoporosis in postmenopausal women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/3/39990\">",
"           Overview of vitamin D",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/21/3417\">",
"           Treatment of vitamin D deficiency in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Carcinoid",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/60/969\">",
"           Clinical characteristics of carcinoid tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/63/9206\">",
"           Clinical features of the carcinoid syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/8/11400\">",
"           Diagnosis of the carcinoid syndrome and tumor localization",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/31/16888\">",
"           Treatment of the carcinoid syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Diabetes insipidus",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/19/41272\">",
"           Benefits and complications associated with kidney-pancreas transplantation in diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/2/21545\">",
"           Clinical manifestations and causes of nephrogenic diabetes insipidus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/47/24312\">",
"           Diagnosis of polyuria and diabetes insipidus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/31/505\">",
"           Treatment of central diabetes insipidus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/32/24071\">",
"           Treatment of nephrogenic diabetes insipidus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/34/6691\">",
"           Urine output in diabetes insipidus",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Diabetes mellitus",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/55/15225\">",
"           General principles of insulin therapy in diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/34/11817\">",
"           Glycemic control and vascular complications in type 1 diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/25/7578\">",
"           Glycemic control and vascular complications in type 2 diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/39/44664\">",
"           Hypoglycemia in adults: Clinical manifestations, definition, and causes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/58/25511\">",
"           Insulin action",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/46/41702\">",
"           Insulin secretion and pancreatic beta-cell function",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/39/26233\">",
"           Management of diabetes mellitus in hospitalized patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/38/36458\">",
"           Overview of medical care in adults with diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/63/7162\">",
"           Pancreas and islet transplantation in diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/16/7434\">",
"           Patient selection for and immunologic issues relating to kidney-pancreas transplantation in diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/63/29688\">",
"           Perioperative management of diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/39/36472\">",
"           Renal transplantation in diabetic nephropathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/47/32502\">",
"           Susceptibility to infections in persons with diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/48/15114\">",
"           Treatment of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Fluid and electrolytes",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/57/29589\">",
"           Acid-base and electrolyte abnormalities with diarrhea or ureteral diversion",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/13/5338\">",
"           Approach to the patient with hypertension and hypokalemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/58/13220\">",
"           Causes and treatment of hypermagnesemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/44/3781\">",
"           Causes of lactic acidosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/35/39479\">",
"           Clinical manifestations and evaluation of metabolic alkalosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/28/20934\">",
"           Diagnostic approach to hypercalcemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/13/34005\">",
"           Diagnostic approach to hypocalcemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/44/9930\">",
"           Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/9/9366\">",
"           Evaluation of the patient with hypokalemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/20/21832\">",
"           Evaluation of the patient with hyponatremia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/50/29482\">",
"           Hepatorenal syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/48/41734\">",
"           Hypercalcemia of malignancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/42/28324\">",
"           Hypophosphatemia in the alcoholic patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/7/34935\">",
"           Maintenance and replacement fluid therapy in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/58/23464\">",
"           Manifestations of hyponatremia and hypernatremia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/34/18986\">",
"           Overview of the treatment of hyponatremia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/28/10692\">",
"           Pathogenesis of metabolic alkalosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/18/25891\">",
"           Potassium balance in acid-base disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/8/23685\">",
"           Relation between total and ionized serum calcium concentration",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/43/36533\">",
"           Serum anion gap in conditions other than metabolic acidosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/41/27288\">",
"           Simple and mixed acid-base disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/9/32914\">",
"           Symptoms of hypermagnesemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/54/17258\">",
"           Treatment and prevention of hyperkalemia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/42/16041\">",
"           Treatment of hypercalcemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/37/44632\">",
"           Treatment of hypocalcemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/14/14568\">",
"           Treatment of metabolic alkalosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/20/13639\">",
"           Treatment of severe hypovolemia or hypovolemic shock in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/18/11558\">",
"           Urine anion and osmolal gaps in metabolic acidosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Gastrointestinal hormones",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/33/16917\">",
"           Overview of gastrointestinal peptides in health and disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/51/35638\">",
"           Physiology of cholecystokinin",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/9/25751\">",
"           Physiology of gastrin",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/8/22660\">",
"           Synthesis, secretion, and regulation of gastrointestinal peptides",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Glucocorticoid therapy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/61/31703\">",
"           Determinants of glucocorticoid dosing",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/37/28249\">",
"           Glucocorticoid effects on the immune system",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/37/22103\">",
"           Glucocorticoid withdrawal",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/62/17384\">",
"           The surgical patient taking glucocorticoids",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Multiple endocrine neoplasia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/42/8872\">",
"           Approach to therapy in multiple endocrine neoplasia type 2",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/16/22794\">",
"           Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/14/43240\">",
"           Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/49/17174\">",
"           Multiple endocrine neoplasia type 1: Definition and genetics",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/61/38871\">",
"           Multiple endocrine neoplasia type 1: Treatment",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Obesity",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/21/3418\">",
"           Etiology and natural history of obesity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/23/16758\">",
"           Ghrelin",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/35/30266\">",
"           Health hazards associated with obesity in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/57/28567\">",
"           Insulin resistance: Definition and clinical spectrum",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/38/13929\">",
"           Pathogenesis of obesity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/50/13094\">",
"           Physiology of leptin",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/2/32810\">",
"           Postoperative management of the critically ill obese patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/20/12615\">",
"           Screening for and clinical evaluation of obesity in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/31/33274\">",
"           Surgical management of severe obesity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/11/32954\">",
"           The metabolic syndrome (insulin resistance syndrome or syndrome X)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pancreas",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/57/18330\">",
"           Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine tumors (islet-cell tumors)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/10/14504\">",
"           Clinical manifestations and diagnosis of Zollinger-Ellison syndrome (gastrinoma)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/35/22071\">",
"           Diagnostic dilemmas in hypoglycemia: Illustrative cases",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/57/31640\">",
"           Glucagonoma and the glucagonoma syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/46/41702\">",
"           Insulin secretion and pancreatic beta-cell function",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/30/12777\">",
"           Insulinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/51/6968\">",
"           Management and prognosis of the Zollinger-Ellison syndrome (gastrinoma)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/30/43496\">",
"           Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/32/6665\">",
"           Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/46/39658\">",
"           Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/34/3623\">",
"           Somatostatinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/23/6522\">",
"           Structure and function of the insulin receptor",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/59/16311\">",
"           The VIPoma syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Parathyroid",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/19/1338\">",
"           Clinical manifestations of primary hyperparathyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/26/5545\">",
"           Diagnosis and differential diagnosis of primary hyperparathyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/13/3287\">",
"           Hungry bone syndrome following parathyroidectomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/3/9273\">",
"           Indications for parathyroidectomy in end-stage renal disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/40/9864\">",
"           Intraoperative parathyroid hormone monitoring",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/47/8954\">",
"           Management of primary hyperparathyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/8/40073\">",
"           Parathyroid and mineral metabolism after renal transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/23/13688\">",
"           Parathyroid carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/28/40387\">",
"           Parathyroid cysts",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/0/35850\">",
"           Parathyroid exploration for primary hyperparathyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/58/21416\">",
"           Parathyroid hormone assays and their clinical use",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/56/36744\">",
"           Parathyroid hormone secretion and action",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/41/30361\">",
"           Pathogenesis and etiology of primary hyperparathyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/60/18377\">",
"           Preoperative localization for parathyroid surgery in patients with primary hyperparathyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/23/29045\">",
"           Surgical anatomy of the parathyroid glands",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pituitary",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/3/30776\">",
"           Causes and clinical manifestations of acromegaly",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/41/22167\">",
"           Causes of hyperprolactinemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/18/29992\">",
"           Causes, presentation, and evaluation of sellar masses",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/61/22489\">",
"           Clinical manifestations and diagnosis of gonadotroph and other clinically nonfunctioning pituitary adenomas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/51/19254\">",
"           Clinical manifestations and diagnosis of hyperprolactinemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/60/24520\">",
"           Craniopharyngioma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/4/43076\">",
"           Diagnosis of acromegaly",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/28/41413\">",
"           Diagnosis of hypopituitarism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/30/25059\">",
"           Hypothalamic-pituitary axis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/43/12981\">",
"           Incidentally discovered sellar masses (pituitary incidentalomas)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/50/22312\">",
"           Pituitary and adrenal gland dysfunction in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/9/13464\">",
"           Pituitary gigantism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/20/327\">",
"           Thyrotropin (TSH)-secreting pituitary adenomas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/9/7322\">",
"           Treatment of acromegaly",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/41/8857\">",
"           Treatment of gonadotroph and other clinically nonfunctioning adenomas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/52/31561\">",
"           Treatment of hyperprolactinemia due to lactotroph adenoma and other causes",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Reproductive endocrine female",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/2/7210\">",
"           Mechanisms of action of selective estrogen receptor modulators",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/53/25434\">",
"           Menopausal hot flashes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/48/19210\">",
"           Pathogenesis, clinical features, and diagnosis of endometriosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/2/27685\">",
"           Physiology of the normal menstrual cycle",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/11/11449\">",
"           Postmenopausal hormone therapy and the risk of breast cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/26/17831\">",
"           Postmenopausal hormone therapy in the prevention and treatment of osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/23/32122\">",
"           Postmenopausal hormone therapy: Benefits and risks",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/42/25258\">",
"           Sexual dysfunction in women: Epidemiology, risk factors, and evaluation",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Reproductive endocrine male",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/47/27384\">",
"           Causes and evaluation of gynecomastia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/9/6294\">",
"           Epidemiology and pathogenesis of gynecomastia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/47/760\">",
"           Management of gynecomastia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         SIADH",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/46/7913\">",
"           Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/57/17306\">",
"           Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Thyroid",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/10/23721\">",
"           Anaplastic thyroid cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/56/24452\">",
"           Atlas of thyroid cytopathology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/7/27770\">",
"           Central and lateral compartment lymphadenectomy (neck dissection) for differentiated thyroid cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/2/46\">",
"           Clinical manifestations and evaluation of obstructive or substernal goiter",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/10/14503\">",
"           Clinical manifestations of hypothyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/16/14599\">",
"           Clinicopathologic staging of differentiated thyroid cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/15/37111\">",
"           Cystic thyroid nodules",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/7/26744\">",
"           Diagnosis of and screening for hypothyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/57/26520\">",
"           Diagnosis of hyperthyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/53/28506\">",
"           Diagnostic approach to and treatment of thyroid nodules",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/0/4103\">",
"           Disorders that cause hyperthyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/47/42744\">",
"           Disorders that cause hypothyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/4/4165\">",
"           Exogenous hyperthyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/17/39191\">",
"           External beam radiotherapy in the treatment of thyroid cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/36/12871\">",
"           Hyperthyroidism during pregnancy: Clinical manifestations, diagnosis, and causes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/48/42760\">",
"           Hyperthyroidism during pregnancy: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/57/31642\">",
"           Initial and reoperative thyroidectomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/59/39864\">",
"           Iodine deficiency disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/33/3608\">",
"           Laboratory assessment of thyroid function",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/21/9560\">",
"           Medullary thyroid cancer: Clinical manifestations, diagnosis, and staging",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/23/38263\">",
"           Medullary thyroid cancer: Treatment and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/2/4137\">",
"           Nonthyroid surgery in the patient with thyroid disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/11/21688\">",
"           Overview of follicular thyroid cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/15/8440\">",
"           Overview of papillary thyroid cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/60/14279\">",
"           Overview of the clinical manifestations of hyperthyroidism in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/62/21482\">",
"           Overview of the clinical utility of ultrasonography in thyroid disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/17/44313\">",
"           Overview of the management of differentiated thyroid cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/51/16186\">",
"           Overview of thyroid disease in pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/60/1990\">",
"           Overview of thyroid nodule formation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/51/43830\">",
"           Overview of thyroiditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/49/1818\">",
"           Radiation-induced thyroid cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/13/34010\">",
"           Radioiodine treatment of differentiated thyroid cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/39/37496\">",
"           Serum thyroglobulin in the management of differentiated thyroid cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/8/12424\">",
"           Surgery in the treatment of hyperthyroidism: Indications, preoperative preparation, and postoperative follow-up",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/17/44310\">",
"           Surgical anatomy of the thyroid gland",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/6/41064\">",
"           Surgical treatment of differentiated thyroid cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/24/2437\">",
"           Technical aspects of thyroid ultrasound",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/16/25864\">",
"           Thyroglossal duct cysts and ectopic thyroid",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/25/28056\">",
"           Thyroid biopsy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/31/38388\">",
"           Thyroid gland dysfunction in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/61/10200\">",
"           Thyroid hormone action",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/34/33320\">",
"           Thyroid hormone synthesis and physiology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/8/35974\">",
"           Thyroid lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/55/33655\">",
"           Thyroid storm",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/53/43865\">",
"           Treatment of hypothyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/62/32742\">",
"           Treatment of obstructive or substernal goiter",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/4/31814\">",
"           Ultrasound-guided thyroid biopsy",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-BAE2A2EFC5-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f40_44_41666=[""].join("\n");
var outline_f40_44_41666=null;
var title_f40_44_41667="Gonadorelin acetate: Patient drug information";
var content_f40_44_41667=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Gonadorelin acetate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/31/9715?source=see_link\">",
"     see \"Gonadorelin acetate: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F177038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Lutrepulse&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F11358505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691380",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help you get pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F11347484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2980659",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to gonadorelin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2980679",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Cancer where hormones make it grow, ovarian cysts, pituitary tumor, or adrenal gland disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F11347486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697565",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit working out while undergoing ovarian stimulation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697703",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may raise the chance of getting pregnant with more than one baby.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F11358508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698294",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Over stimulation of the ovaries.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F11347488\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699007",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain or soreness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F11358507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695987",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein or into the fatty part of the skin.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F11347485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor to find out what to do.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F11358509\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F11347489\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15999 Version 21.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-76F9A528C7-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_44_41667=[""].join("\n");
var outline_f40_44_41667=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177038\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11358505\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11347484\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11347486\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11358508\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11347488\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11358507\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11347485\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11358509\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11347489\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?9/31/9715?source=related_link\">",
"      Gonadorelin acetate: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_44_41668="Rabeprazole: Patient drug information";
var content_f40_44_41668=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Rabeprazole: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/18/44327?source=see_link\">",
"     see \"Rabeprazole: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/44/43718?source=see_link\">",
"     see \"Rabeprazole: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F10539946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      AcipHex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F216709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Rabeprazole&reg;;",
"     </li>",
"     <li>",
"      Pariet&reg;;",
"     </li>",
"     <li>",
"      Pat-Rabeprazole;",
"     </li>",
"     <li>",
"      PMS-Rabeprazole EC;",
"     </li>",
"     <li>",
"      PRO-Rabeprazole;",
"     </li>",
"     <li>",
"      Rabeprazole EC;",
"     </li>",
"     <li>",
"      RAN&trade;-Rabeprazole;",
"     </li>",
"     <li>",
"      Riva-Rabeprazole EC;",
"     </li>",
"     <li>",
"      Sandoz-Rabeprazole;",
"     </li>",
"     <li>",
"      Teva-Rabeprazole EC",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10019890\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10019892\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691849",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat gastroesophageal reflux disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691503",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat GI (gastrointestinal) ulcers caused by infection.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692103",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat syndromes caused by lots of stomach acid.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10019891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702844",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to rabeprazole or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10019896\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697754",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use care if you have risks for soft, brittle bones called osteoporosis (alcohol use, cigarette smoking, other family members with brittle bones, taking drugs to treat seizures, taking steroids).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10019897\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698108",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Gas.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2769639",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hip, spine, or wrist fractures may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10019899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2769659",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad bone pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699003",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Seizures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10019894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695833",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take 30 minutes before the first meal of the day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695714",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10019895\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10019900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10019901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11016 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-7AD06D259D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_44_41668=[""].join("\n");
var outline_f40_44_41668=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10539946\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216709\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019890\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019892\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019891\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019896\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019897\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019899\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019894\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019895\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019900\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019901\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?43/18/44327?source=related_link\">",
"      Rabeprazole: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/44/43718?source=related_link\">",
"      Rabeprazole: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_44_41669="Free TRAM flap reconstruction after skin sparing mastectomy";
var content_f40_44_41669=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F64061&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F64061&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 555px\">",
"   <div class=\"ttl\">",
"    Free TRAM flap reconstruction after skin sparing mastectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 535px; height: 686px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The free TRAM (transverse rectus abdominus myocutaneous) flap completely detaches and directly transfers the lower abdominal tissue to the mastectomy site. The deep inferior epigastric artery and vein, which provide the vascular supply for the free flap, are anastomosed to local recipient vessels, using either the internal mammary or thoracodorsal arteries and veins. This can be performed to provide immediate or delayed breast reconstruction. In this drawing, a skin sparing mastectomy is depicted. This drawing depicts the blood supply anastomosis to the thoracodorsal vessels, however, the internal mammary site is also used commonly for the site of anastomosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_44_41669=[""].join("\n");
var outline_f40_44_41669=null;
var title_f40_44_41670="Approach to immunizations in healthy adults";
var content_f40_44_41670=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to immunizations in healthy adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/44/41670/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/44/41670/contributors\">",
"     Patricia L Hibberd, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/44/41670/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/44/41670/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/44/41670/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/44/41670/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/44/41670/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 31, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pediatric immunization programs in the United States have been very successful; the majority of preschool children are immunized against targeted diseases and few children die annually of vaccine preventable diseases (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/56/39818?source=see_link&amp;anchor=H3#H3\">",
"     \"Standard immunizations for children and adolescents\", section on 'Vaccination coverage'",
"    </a>",
"    ). There have also been marked improvements in immunization rates in adults 65 years and older, although the rates are lower than in children. This was illustrated in a review from the Centers for Disease Control (CDC) comparing vaccinations in elderly adults in 1989 and 2003: pneumococcal vaccine coverage increased from 15 to 64 percent and annual influenza immunization increased from 33 to 70 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41670/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Immunization rates for younger adults at risk for pneumococcus and influenza remains unacceptably low. Based upon 1995 NHIS data, only 12 percent of adults aged 18 to 49 years at risk of pneumococcal disease have received the vaccine, and only 20 percent of those at risk for influenza have been immunized against influenza in the previous 12 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41670/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Between 50,000 and 70,000 adults die annually of these two vaccine preventable diseases alone. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/12/21705?source=see_link\">",
"     \"Pneumococcal vaccination in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/37002?source=see_link\">",
"     \"Seasonal influenza vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Immunity to tetanus and diphtheria also continues to wane among adults in the United States. In one large serologic survey, only 47 percent of adults over the age of 20 years in the United States had protective antibody to both diseases and only 63 percent of adults with immunity to tetanus also had protective antibody to diphtheria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41670/abstract/5\">",
"     5",
"    </a>",
"    ]. By contrast, 91 percent of children from 6 to 11 years of age had protective antibody to both diseases. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/54/7014?source=see_link\">",
"     \"Tetanus-diphtheria toxoid vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The national goals of Healthy People 2010 include reduction of vaccine preventable disease in adults as well as children. Specific goals directed at adults include: elimination of diphtheria, measles, mumps, rubella, and tetanus, at least a 75 percent reduction in the number of cases of hepatitis A and B, and 90 percent compliance with routine administration of pneumococcal and influenza vaccines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41670/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The principles behind adult immunization, the recommended schedule for healthy adults, and strategies to incorporate these recommendations into practice will be reviewed here. The rationale and risk-benefit considerations for the administration of each vaccine as well as immunizations for selected groups such as immunocompromised individuals, healthy women who are pregnant or breast feeding, the health care worker, and international travelers are discussed separately. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PRINCIPLES OF IMMUNIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of factors are important when administering vaccines to healthy adults. These issues include the type of immunization to be used, safety, the responsibilities of the individual giving the vaccination, and proper storage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Type of immunization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most vaccinations induce active immunity by promoting the development of antibody in the recipient, a response which is expected to be durable. Passive immunization, which usually involves the administration of a globulin product, produces transient immunity for a specific exposure through the transfer of antibody directly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Active",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of active immunization of a vaccine or toxoid is to stimulate the host to produce a primary immune response (usually by inducing B-cell proliferation, antibody response, and T-cell sensitization). If an individual is subsequently exposed to the pathogen against which the vaccine is directed, the exposure results in a secondary response that includes increased proliferation of B-cells and formation of antibodies. The secondary response protects the individual from developing disease, ideally for life.",
"   </p>",
"   <p>",
"    Some vaccines require boosters to sustain protection. Vaccines used for active immunization are derived from whole killed bacteria, live attenuated bacteria or viruses, or antigenic subunits of organisms. Vaccines recommended for healthy adults are the pneumococcal, influenza, hepatitis B, MMR, varicella, and hepatitis A vaccines.",
"   </p>",
"   <p>",
"    Toxoids used for active immunization are bacterial toxins that are modified to render them nontoxic. Toxoids induce the formation of antitoxin antibody. If the host is exposed to the bacterial toxin after immunization, the antitoxin antibody binds to the bacterial toxin, thereby preventing toxin-mediated disease. Toxoids recommended for healthy adults are tetanus and diphtheria toxoid.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Passive",
"    </span>",
"    &nbsp;&mdash;&nbsp;Passive immunization involves administration of antibodies (as intramuscular immune globulin derived from pooled human serum or antitoxin derived from serum harvested from immunized animals). Passive immunization offers short-term protection to people who have been or will be exposed to a specific pathogen and is typically used by immunocompromised patients who are unable to produce an effective immune response with active immunization. Passive immunization is not routinely recommended for healthy adults because the majority of adults are capable of producing a durable immune response through active immunization. Passive immunization is occasionally used for health care workers, pregnant women, and international travelers (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recommended method of storage, preparation, and route of administration of each vaccine is described in the package insert; these instructions must be followed precisely (",
"    <a class=\"graphic graphic_table graphicRef81508 \" href=\"mobipreview.htm?36/23/37245\">",
"     table 1",
"    </a>",
"    ). Recommendations regarding practical issues, such as vaccination spacing and timing, injection techniques, and storage and handling, are also available in the ACIP guidelines, which are available at the CDC's National Center for Immunization and Respiratory Diseases website (",
"    <a class=\"external\" href=\"file://www.cdc.gov/ncird/\">",
"     www.cdc.gov/ncird/",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41670/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most adult vaccines are administered intramuscularly or subcutaneously, usually in or over the deltoid muscle. Deltoid intramuscular injections should be given with a 1 to 1.5 inch needle, to achieve at least 5 mm of muscle penetration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41670/abstract/7\">",
"     7",
"    </a>",
"    ]. The buttock should be avoided for routine vaccine administration, except for large volume injections of immune globulin, because immunogenicity of the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/36/27207?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    , at least, is significantly lower when given in the buttock. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/60/31690?source=see_link\">",
"     \"Hepatitis B virus vaccination\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Subcutaneous injection should be given with a 23 to 25 gauge needle with a needle length of",
"    <span class=\"nowrap\">",
"     5/8",
"    </span>",
"    to",
"    <span class=\"nowrap\">",
"     3/4",
"    </span>",
"    inch. Use of doses other than those specified in the package insert is not recommended.",
"   </p>",
"   <p>",
"    While every effort should be made to adhere to the recommended immunization schedule, it is not necessary to restart the series of any vaccine, even when the interval between doses is prolonged. Subsequent immunizations should continue on the originally recommended immunization schedule.",
"   </p>",
"   <p>",
"    Most widely used vaccines can be administered simultaneously at different sites, without compromising efficacy. For adults of all ages, coadministration of the pneumococcal and influenza vaccine appears safe and does not compromise efficacy of either vaccine. In a Finnish study of 9336 individuals ages 65 years and older, the group of 4755 who received simultaneous pneumococcal and influenza vaccines experienced approximately double the number of mild local reactions and fevers compared to the 4581 receiving influenza vaccine alone (441 per 1000 vaccinations versus 284 per 1000 for local reactions and 10 per 1000 versus 24 per 1000 for fever) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41670/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/12/21705?source=see_link\">",
"     \"Pneumococcal vaccination in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/37002?source=see_link\">",
"     \"Seasonal influenza vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Limitations of coadministration of vaccines include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Live virus vaccines should either be administered on the same day, or subsequent immunization with live virus vaccines should be delayed one month to avoid the theoretical concern that the immune response to one or both might be impaired.",
"     </li>",
"     <li>",
"      Immune globulins should not be administered along with live virus vaccines because the passively administered antibodies can interfere with the vaccine response (this limitation does not apply to inactivated vaccines or oral polio and yellow fever vaccines).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If administration of immune globulin (or blood products containing significant amounts of immune globulin) becomes necessary within 14 days of administration of MMR, either vaccination antibody titers should be checked to ensure that the MMR vaccine was effective or the MMR vaccine should be repeated 3 to 11 months after the initial vaccination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41670/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Healthcare provider responsibilities",
"    </span>",
"    &nbsp;&mdash;&nbsp;The National Childhood Vaccine Injury Act of 1986 requires that health care providers who administer vaccines follow vaccine directives, maintain records, and report adverse events. Providers are expected to use vaccine information statements available from the Centers for Disease Control and Prevention (CDC) and local or state health departments for MMR, polio, and pertussis vaccines, as well as tetanus and diphtheria toxoids (pertussis vaccine is recommended for children, not adults).",
"   </p>",
"   <p>",
"    It is also vital to maintain permanent immunization records that include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The type of vaccine and dose",
"     </li>",
"     <li>",
"      The site and route of administration",
"     </li>",
"     <li>",
"      The date that the vaccine was administered",
"     </li>",
"     <li>",
"      The date that the next dose is due",
"     </li>",
"     <li>",
"      The manufacturer and lot number",
"     </li>",
"     <li>",
"      The name, address, and title of the person administering the vaccine",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most vaccines are safe to administer, causing only minor side effects. The more common problem with immunization is the missed opportunity to vaccinate based in part upon public misconceptions about the safety of immunization. Many vaccines and toxoids cause side effects such as fever, local reactions at the site of injection, or even serum sickness-like reactions. These adverse reactions can be caused by the immunogenic moiety in the vaccine or by trace amounts of antibiotics, preservatives, stabilizers, and residual animal proteins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41670/abstract/10\">",
"     10",
"    </a>",
"    ]. These side effects are not considered true contraindications to vaccination.",
"   </p>",
"   <p>",
"    True contraindications to vaccination are rare and include severe hypersensitivity reactions, such as anaphylaxis and severe neurologic complications. Administration of live virus vaccines to immunocompromised patients is also contraindicated. Vaccination should be avoided only if true contraindications are present (",
"    <a class=\"graphic graphic_table graphicRef75067 \" href=\"mobipreview.htm?8/15/8444\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41670/abstract/9,11\">",
"     9,11",
"    </a>",
"    ]. The following are",
"    <strong>",
"     NOT",
"    </strong>",
"    contraindications to immunization:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Current or recent mild illness, with or without low grade fever",
"     </li>",
"     <li>",
"      Current or recent antibiotic therapy",
"     </li>",
"     <li>",
"      Previous mild to moderate local tenderness, redness, swelling, or fever less than 40.5&ordm;C after any vaccination",
"     </li>",
"     <li>",
"      Personal history of allergies, except those listed in the following Table (",
"      <a class=\"graphic graphic_table graphicRef75067 \" href=\"mobipreview.htm?8/15/8444\">",
"       table 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Family history of adverse reactions to immunization",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Adverse event reporting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse events associated with vaccines should be reported to the United States Department of Health and Human Services using the Vaccine Adverse Events Reporting System (VAERS,",
"    <a class=\"external\" href=\"file://vaers.hhs.gov/index\">",
"     file://vaers.hhs.gov/index",
"    </a>",
"    , telephone number 1-800-822-7967). Reportable events include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Anaphylaxis or anaphylactic shock within 7 days of any vaccine",
"     </li>",
"     <li>",
"      Encephalopathy, encephalitis, or seizures",
"     </li>",
"     <li>",
"      Any sequelae of reportable events",
"     </li>",
"     <li>",
"      Any other serious or unusual event",
"     </li>",
"     <li>",
"      Vaccine side effects that are listed as contraindications to future vaccination in the package insert",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Vaccine specific reportable events include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tetanus: Brachial neuritis within 28 days",
"     </li>",
"     <li>",
"      Pertussis: Encephalopathy or encephalitis within 7 days",
"     </li>",
"     <li>",
"      Measles, mumps, and or rubella: Encephalopathy or encephalitis within 15 days",
"     </li>",
"     <li>",
"      Rubella: Chronic arthritis within 6 weeks",
"     </li>",
"     <li>",
"      Measles: Thrombocytopenic purpura within 7 to 30 days; vaccine-strain measles infection in an immunodeficient recipient within six months of measles vaccination",
"     </li>",
"     <li>",
"      Oral polio: Paralytic polio or vaccine-strain polio within 30 days to six months (this vaccine is no longer used in the United States)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     IMMUNIZATION SCHEDULE FOR HEALTHY ADULTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunization recommendations in the United States result from policies developed by the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) (",
"    <a class=\"graphic graphic_figure graphicRef82634 \" href=\"mobipreview.htm?36/52/37701\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef62130 \" href=\"mobipreview.htm?41/17/42263\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    ACIP statements are published in the Morbidity and Mortality Weekly Report (MMWR) and may be obtained from the CDC's Immunization Hotline (1-800-232-2522) or downloaded from the CDC's website (",
"    <a class=\"external\" href=\"file://www.cdc.gov/mmwr\">",
"     www.cdc.gov/mmwr",
"    </a>",
"    ). Additional advice can be obtained from the Division of Immunization at the CDC (1-404-639-8225).",
"   </p>",
"   <p>",
"    The Infectious Disease Society of America issued practice guidelines for immunizations in 2009 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41670/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     IMMUNIZATIONS AND PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunizations in pregnancy are discussed in detail separately (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/53/32602?source=see_link\">",
"     \"Immunizations during pregnancy\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     STRATEGIES TO INCREASE IMMUNIZATION IN ADULTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Administration of the vaccines included in this topic review is recommended by the Advisory Committee on Immunization Practices, the American College of Physicians, the American Academy of Family Physicians, and the American Academy of Pediatrics. Medicare Part B reimburses for both the influenza and pneumococcal vaccine. Despite the institutional support for immunization, vaccine delivery to adults is poor. Barriers to immunization of adults include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Missed opportunities during contacts with health care providers in offices, outpatient clinics, and hospitals [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/44/41670/abstract/12\">",
"       12",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Lack of vaccine delivery systems in the public and private sectors that can reach adults in different settings (eg, the workplace)",
"     </li>",
"     <li>",
"      Patient and provider fears about adverse events following vaccination",
"     </li>",
"     <li>",
"      Provider concerns about efficacy of individual vaccines",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are limited data on the effectiveness of various strategies to improve adult immunization and many unanswered questions. Possible strategies include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Age-based strategies &mdash; Any encounter with an adult aged 50 and over can be used to review immunization status [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/44/41670/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Provider-based strategies &mdash; Practice-based tracking systems that identify high risk adults remind physicians of the need to improve immunization rates, as does the use of preventative checklists [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/44/41670/abstract/13,14\">",
"       13,14",
"      </a>",
"      ]. Health maintenance sheets can be placed at the front of all patient charts and can be used to generate standing orders.",
"     </li>",
"     <li>",
"      Hospital-based strategies &mdash; Using a standing order (eg, on admission or discharge), rather than requiring a physician's signature, has been successfully used by certain institutions for high-risk patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/44/41670/abstract/15\">",
"       15",
"      </a>",
"      ]. High-risk patients can be identified by physicians, nurses, pharmacists, and infection control practitioners or by computerized systems searching for high-risk diagnoses and patient age. By contrast, inclusion of a guideline to administer pneumococcal vaccine prior to discharge as part of a pneumonia clinical pathway in Connecticut did not result in increased vaccination rates among adults [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/44/41670/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Community-based programs &mdash; Vaccine coverage improves when public health departments specifically promote and offer vaccines [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/44/41670/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Immunization as a measure of quality of care &mdash; The Infectious Diseases Society of America issued an Executive Summary on Immunization Coverage in the US, which cited the need to promote immunization as an important indicator of health care quality in managed care and other organizations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/44/41670/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A meta-analysis of 41 studies on the use of reminders to patients found that Immunization rates improved for those reminded in 80 percent of the studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41670/abstract/19\">",
"     19",
"    </a>",
"    ]. This was true for all of the different practice settings; telephone reminders were the most effective but also the most costly.",
"   </p>",
"   <p>",
"    A systematic review by the Task Force on Community Preventive Services evaluated 35 studies on the effectiveness of interventions to improve targeted vaccination coverage for influenza, pneumococcal and hepatitis B vaccines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41670/abstract/20\">",
"     20",
"    </a>",
"    ]. Provider reminder systems were the only strategy identified to be effective when implemented alone.",
"   </p>",
"   <p>",
"    However, when interventions were implemented in combination, the combination of enhanced access to vaccination services (expanded access in health-care settings or reduced client out-of-pocket costs) with either a provider- or system-based intervention (standing orders, provider reminder systems, or provider assessment and feedback) or an intervention to increase client or community demand for vaccination (client reminders or client education).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/4/23619?source=see_link\">",
"       \"Patient information: Vaccines for adults (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/48/12035?source=see_link\">",
"       \"Patient information: Vaccines (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/52/8003?source=see_link\">",
"       \"Patient information: Vaccines and pregnancy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/25/39318?source=see_link\">",
"       \"Patient information: Adult vaccines (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/7/17522?source=see_link\">",
"       \"Patient information: Vaccination during pregnancy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26202770\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pediatric immunization programs in the United States have been very successful; the majority of preschool children are immunized against targeted diseases and few children die annually of vaccine preventable diseases. There have also been marked improvements in immunization rates in adults 65 years and older, although the rates are lower than in children. Immunization rates for younger adults at risk for pneumococcus and influenza remain unacceptably low. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most vaccinations induce active immunity by promoting the development of antibody in the recipient, a response which is expected to be durable. Passive immunization, which usually involves the administration of a globulin product, produces transient immunity for a specific exposure through the transfer of antibody directly. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Type of immunization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The recommended method of storage, preparation, and route of administration of each vaccine is described in the package insert; these instructions must be followed precisely (",
"      <a class=\"graphic graphic_table graphicRef81508 \" href=\"mobipreview.htm?36/23/37245\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Administration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adverse events associated with vaccines should be reported to the United States Department of Health and Human Services using the Vaccine Adverse Events Reporting System (VAERS,",
"      <a class=\"external\" href=\"file://vaers.hhs.gov/index\">",
"       file://vaers.hhs.gov/index",
"      </a>",
"      , telephone number 1-800-822-7967). Reportable events are listed above. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Adverse event reporting'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immunization recommendations in the United States result from policies developed by the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (",
"      <a class=\"graphic graphic_figure graphicRef82634 \" href=\"mobipreview.htm?36/52/37701\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef62130 \" href=\"mobipreview.htm?41/17/42263\">",
"       figure 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Immunization schedule for healthy adults'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of strategies have been proposed for improving adult immunization rates, including age-based strategies, provider-based strategies, hospital-based strategies, and community-based programs. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Strategies to increase immunization in adults'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41670/abstract/1\">",
"      Centers for Disease Control and Prevention (CDC). Influenza and pneumococcal vaccination coverage among persons aged &gt; or =65 years and persons aged 18-64 years with diabetes or asthma--United States, 2003. MMWR Morb Mortal Wkly Rep 2004; 53:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41670/abstract/2\">",
"      Centers for Disease Control and Prevention. Influenza, pneumococcal and tetanus toxoid vaccination of adutls &mdash; United States, 1993-1997. MMWR Morb Mortal Wkly Rep 2000; 49(SS-9):39.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Healthy People 2010: Objectives for Improving Health.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41670/abstract/4\">",
"      Gardner P, Eickhoff T, Poland GA, et al. Adult immunizations. Ann Intern Med 1996; 124:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41670/abstract/5\">",
"      McQuillan GM, Kruszon-Moran D, Deforest A, et al. Serologic immunity to diphtheria and tetanus in the United States. Ann Intern Med 2002; 136:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41670/abstract/6\">",
"      National Center for Immunization and Respiratory Diseases. General recommendations on immunization --- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41670/abstract/7\">",
"      Poland GA, Borrud A, Jacobson RM, et al. Determination of deltoid fat pad thickness. Implications for needle length in adult immunization. JAMA 1997; 277:1709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41670/abstract/8\">",
"      Honkanen PO, Keistinen T, Kivel&auml; SL. Reactions following administration of influenza vaccine alone or with pneumococcal vaccine to the elderly. Arch Intern Med 1996; 156:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41670/abstract/9\">",
"      Pickering LK, Baker CJ, Freed GL, et al. Immunization programs for infants, children, adolescents, and adults: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41670/abstract/10\">",
"      Centers for Disease Control and Prevention (CDC). Carbon monoxide poisonings associated with snow-obstructed vehicle exhaust systems--Philadelphia and New York City, January 1996. MMWR Morb Mortal Wkly Rep 1996; 45:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41670/abstract/11\">",
"      Centers for Disease Control and Prevention (CDC). Update: influenza activity--United States, 1993-94 season. MMWR Morb Mortal Wkly Rep 1994; 43:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41670/abstract/12\">",
"      Centers for Disease Control and Prevention (CDC). Missed opportunities for pneumococcal and influenza vaccination of Medicare pneumonia inpatients--12 western states, 1995. MMWR Morb Mortal Wkly Rep 1997; 46:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41670/abstract/13\">",
"      Buffington J, Bell KM, LaForce FM. A target-based model for increasing influenza immunizations in private practice. Genesee Hospital Medical Staff. J Gen Intern Med 1991; 6:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41670/abstract/14\">",
"      Clancy CM, Gelfman D, Poses RM. A strategy to improve the utilization of pneumococcal vaccine. J Gen Intern Med 1992; 7:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41670/abstract/15\">",
"      Crouse BJ, Nichol K, Peterson DC, Grimm MB. Hospital-based strategies for improving influenza vaccination rates. J Fam Pract 1994; 38:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41670/abstract/16\">",
"      Metersky ML, Fine JM, Tu GS, et al. Lack of effect of a pneumonia clinical pathway on hospital-based pneumococcal vaccination rates. Am J Med 2001; 110:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41670/abstract/17\">",
"      Centers for Disease Control (CDC). Pneumococcal immunization program--California, 1986-1988. MMWR Morb Mortal Wkly Rep 1989; 38:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41670/abstract/18\">",
"      Immunization Work Group of the National and Global Public Health Committee of the Infectious Diseases Society of America. Executive summary--Actions to strengthen adult and adolescent immunization coverage in the United States: policy principles of the Infectious Diseases Society of America. Clin Infect Dis 2007; 44:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41670/abstract/19\">",
"      Szilagyi PG, Bordley C, Vann JC, et al. Effect of patient reminder/recall interventions on immunization rates: A review. JAMA 2000; 284:1820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41670/abstract/20\">",
"      Willis BC, Ndiaye SM, Hopkins DP, et al. Improving influenza, pneumococcal polysaccharide, and hepatitis B vaccination coverage among adults aged &lt;65 years at high risk: a report on recommendations of the Task Force on Community Preventive Services. MMWR Recomm Rep 2005; 54:1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3884 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-183.1.191.153-340D2F8564-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_44_41670=[""].join("\n");
var outline_f40_44_41670=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26202770\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PRINCIPLES OF IMMUNIZATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Type of immunization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Active",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Passive",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Healthcare provider responsibilities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Safety",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Adverse event reporting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      IMMUNIZATION SCHEDULE FOR HEALTHY ADULTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      IMMUNIZATIONS AND PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      STRATEGIES TO INCREASE IMMUNIZATION IN ADULTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26202770\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3884\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3884|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/52/37701\" title=\"figure 1\">",
"      Vax schedule healthy adult",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?41/17/42263\" title=\"figure 2\">",
"      Vaccine schedule based on medical conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3884|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/23/37245\" title=\"table 1\">",
"      Vaccine administration guidelines for adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/15/8444\" title=\"table 2\">",
"      Vaccine true contraindications",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/60/31690?source=related_link\">",
"      Hepatitis B virus vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/53/32602?source=related_link\">",
"      Immunizations during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/25/39318?source=related_link\">",
"      Patient information: Adult vaccines (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/7/17522?source=related_link\">",
"      Patient information: Vaccination during pregnancy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/48/12035?source=related_link\">",
"      Patient information: Vaccines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/52/8003?source=related_link\">",
"      Patient information: Vaccines and pregnancy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/4/23619?source=related_link\">",
"      Patient information: Vaccines for adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/12/21705?source=related_link\">",
"      Pneumococcal vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/37002?source=related_link\">",
"      Seasonal influenza vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/56/39818?source=related_link\">",
"      Standard immunizations for children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/54/7014?source=related_link\">",
"      Tetanus-diphtheria toxoid vaccination in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_44_41671="Amitriptyline and chlordiazepoxide: Drug information";
var content_f40_44_41671=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Amitriptyline and chlordiazepoxide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?14/61/15317?source=see_link\">",
"    see \"Amitriptyline and chlordiazepoxide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708614\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F133889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidepressant, Tricyclic (Tertiary Amine);",
"     </li>",
"     <li>",
"      Benzodiazepine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F133879\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Depression and anxiety: Oral: Initial: 3-4 tablets in divided doses; this may be increased to 6 tablets/day as required. Some patients respond to smaller doses and can be maintained on 2 tablets.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F133880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15671612\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15671613\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F133864\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: 12.5/5: Amitriptyline hydrochloride 12.5 mg and chlordiazepoxide 5 mg; 25/10: Amitriptyline hydrochloride 25 mg and chlordiazepoxide 10 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F133852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F133891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-IV",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874547\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088622.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088622.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F133866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of moderate-to-severe anxiety and/or agitation and depression",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9954485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - high [moderate for SIADH]; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F133887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F133869\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to benzodiazepines, tricyclic antidepressants, or any component of the formulation; depression of CNS; MAO inhibitors; acute recovery phase following MI; angle-closure glaucoma",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F133855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Major psychiatric warnings:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Suicidal thinking/behavior:",
"     <b>",
"      [U.S. Boxed Warning]: Antidepressants increase the risk of suicidal thinking and behavior in children, adolescents, and young adults (18-24 years of age) with major depressive disorder (MDD) and other psychiatric disorders;",
"     </b>",
"     consider risk prior to prescribing. Short-term studies did not show an increased risk in patients &gt;24 years of age and showed a decreased risk in patients &ge;65 years. Closely monitor patients for clinical worsening, suicidality, or unusual changes in behavior, particularly during the initial 1-2 months of therapy or during periods of dosage adjustments (increases or decreases); the patient&rsquo;s family or caregiver should be instructed to closely observe the patient and communicate condition with healthcare provider. A medication guide concerning the use of antidepressants should be dispensed with each prescription.",
"     <b>",
"      Amitriptyline and chlordiazepoxide combination is FDA approved for depression associated with anxiety in children &ge;12 years of age.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; The possibility of a suicide attempt is inherent in major depression and may persist until remission occurs. Patients treated with antidepressants should be observed for clinical worsening and suicidality, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases. Worsening depression and severe abrupt suicidality that are not part of the presenting symptoms may require discontinuation or modification of drug therapy. Use caution in high-risk patients during initiation of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prescriptions should be written for the smallest quantity consistent with good patient care. The patient's family or caregiver should be alerted to monitor patients for the emergence of suicidality and associated behaviors such as anxiety, agitation, panic attacks, insomnia, irritability, hostility, impulsivity, akathisia, hypomania, and mania; patients should be instructed to notify their healthcare provider if any of these symptoms or worsening depression or psychosis occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anterograde amnesia: Benzodiazepines have been associated with anterograde amnesia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anticholinergic effects: May cause anticholinergic effects (constipation, xerostomia, blurred vision, urinary retention); use with caution in patients with decreased gastrointestinal motility, paralytic ileus, urinary retention, BPH, xerostomia, or visual problems. The degree of anticholinergic blockade produced by amitriptyline is very high relative to other antidepressants.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Orthostatic hypotension: May cause orthostatic hypotension (risk is very high relative to other antidepressants); use with caution in patients at risk of this effect or in those who would not tolerate transient hypotensive episodes (cerebrovascular disease, cardiovascular disease, hypovolemia, or concurrent medication use which may predispose to hypotension/bradycardia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Paradoxical reactions: Paradoxical reactions, including hyperactive or aggressive behavior, have been reported with benzodiazepines, particularly in adolescent/pediatric or psychiatric patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedation: Both agents may cause sedation, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). The degree of sedation is very high relative to other antidepressants.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; SIADH and hyponatremia: Has been associated with the development of SIADH and hyponatremia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with a history of cardiovascular disease (including previous MI, stroke, tachycardia, or conduction abnormalities); the risk conduction abnormalities with amitriptyline is high relative to other antidepressants.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Depression: Use chlordiazepoxide with caution in patients with depression, particularly if suicidal risk may be present.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug abuse: Use chlordiazepoxide with caution in patients with a history of drug abuse or acute alcoholism; potential for drug dependency exists. Tolerance, psychological and physical dependence may occur with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use amitriptyline with caution in patients with diabetes mellitus; may alter glucose regulation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use both agents with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Impaired gag reflex: Use chlordiazepoxide  with caution in patients with an impaired gag reflex.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Mania/hypomania: May worsen psychosis in some patients or precipitate a shift to mania or hypomania in patients with bipolar disorder. Monotherapy in patients with bipolar disorder should be avoided. Patients presenting with depressive symptoms should be screened for bipolar disorder.",
"     <b>",
"      This combination is not FDA approved for the treatment of bipolar depression.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Porphyria: Use chlordiazepoxide with caution in patients with porphyria.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use both agents with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use chlordiazepoxide with caution in patients with respiratory disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorder: Use with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications which may lower seizure threshold.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with hyperthyroidism or those receiving thyroid supplementation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depressants/psychoactive medications: Use chlordiazepoxide with caution in patients receiving other CNS depressants or psychoactive medication.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Debilitated patients: Use chlordiazepoxide with caution in debilitated patients; active metabolites with extended half-lives may lead to delayed accumulation and adverse effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: In older adults, benzodiazepines increase the risk of impaired cognition, delirium, falls, fractures, and motor vehicle accidents. Due to increased sensitivity in this age group and slower metabolism of long-acting agents (such as chlordiazepoxide), avoid use for treatment of insomnia, agitation, or delirium. Avoid amitriptyline use in this age group due to its potent anticholinergic and sedative properties, and potential to cause orthostatic hypotension. In addition, may also cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion or hyponatremia; monitor sodium closely with initiation or dosage adjustments in older adults (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Chlordiazepoxide does not have analgesic, antidepressant, or antipsychotic properties.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Discontinuation of therapy: Amitriptyline therapy should not be abruptly discontinued in patients receiving high doses for prolonged periods. Rebound or withdrawal symptoms may occur following abrupt discontinuation of chlordiazepoxide or large decreases in dose. Use caution when reducing dose or withdrawing therapy; decrease slowly and monitor for withdrawal symptoms. Flumazenil may cause withdrawal in patients receiving long-term benzodiazepine therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electroconvulsive therapy: May increase the risks associated with electroconvulsive therapy; consider discontinuing, when possible, prior to ECT treatment.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F133884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F133859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Direct-Acting): Tricyclic Antidepressants may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Agonists: Tricyclic Antidepressants may enhance the vasopressor effect of Alpha1-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha2-Agonists: Tricyclic Antidepressants may diminish the antihypertensive effect of Alpha2-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Apraclonidine; Brimonidine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Altretamine: May enhance the orthostatic hypotensive effect of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Tricyclic Antidepressants may enhance the stimulatory effect of Amphetamines. Tricyclic Antidepressants may also potentiate the cardiovascular effects of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of Benzodiazepines (metabolized by oxidation). Management: The following combinations are specifically contraindicated: itraconazole with alprazolam, estazolam, oral midazolam, or triazolam; ketoconazole with alprazolam, estazolam, or triazolam.  Consider initial dose reductions of other benzodiazepines.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: May increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aspirin: Antidepressants (Tricyclic, Tertiary Amine) may enhance the antiplatelet effect of Aspirin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May increase the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: Tricyclic Antidepressants may enhance the adverse/toxic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BuPROPion: May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cinacalcet: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cisapride: Amitriptyline may enhance the arrhythmogenic effect of Cisapride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Benzodiazepines may enhance the adverse/toxic effect of CloZAPine.  Management: Consider decreasing the dose of (or possibly discontinuing) benzodiazepines prior to initiating clozapine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): May increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Tricyclic Antidepressants may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Dexmethylphenidate may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disulfiram: May increase the serum concentration of ChlordiazePOXIDE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DULoxetine: May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: May increase the serum concentration of Benzodiazepines (metabolized by oxidation). Specifically, the active metabolite aprepitant is likely responsible for this effect.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Benzodiazepines may increase the serum concentration of Fosphenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Tricyclic Antidepressants may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linezolid: May enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: May enhance the neurotoxic effect of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the serotonergic effect of Tricyclic Antidepressants. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylene Blue: Tricyclic Antidepressants may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Methylphenidate may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Management: Seek alternatives to this combination when possible. Monitor patients receiving metoclopramide with tricyclic antidepressants for signs of extrapyramidal symptoms, neuroleptic malignant syndrome, and serotonin syndrome.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: May enhance the adverse/toxic effect of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Antidepressants (Tricyclic, Tertiary Amine) may enhance the antiplatelet effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (Nonselective): Antidepressants (Tricyclic, Tertiary Amine) may enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OLANZapine: May enhance the adverse/toxic effect of Benzodiazepines. Management: Avoid concomitant use of parenteral benzodiazepines and IM olanzapine due to risks of additive adverse events (e.g., cardiorespiratory depression). Olanzapine prescribing information provides no specific recommendations regarding oral administration.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Benzodiazepines may increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Lansoprazole; Pantoprazole; RABEprazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Tricyclic Antidepressants may enhance the QTc-prolonging effect of QuiNIDine. QuiNIDine may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Citalopram; Escitalopram; PARoxetine; Sertraline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: Benzodiazepines may enhance the CNS depressant effect of Sodium Oxybate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Tricyclic Antidepressants may enhance the adverse/toxic effect of Sodium Phosphates. Specifically, the risk of seizure and/or loss of consciousness may be increased in patients with significant sodium phosphate induced fluid/electrolyte abnormalities.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May increase the metabolism of Tricyclic Antidepressants. The risk of serotonin syndrome may theoretically be increased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May increase the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Cyclic Antidepressants may enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Terbinafine (Systemic): May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: May diminish the therapeutic effect of Benzodiazepines.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: Tricyclic Antidepressants may enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Tricyclic Antidepressants may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: Tricyclic Antidepressants may increase the serum concentration of Yohimbine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the therapeutic effect of Antianxiety Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14471180\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F133882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14471181\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F133871\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Chlordiazepoxide-Amitriptyline Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-12.5 mg (100): $111.24",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-25 mg (100): $156.94",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F4794408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Suicidal ideation (especially at the beginning of therapy or when doses are increased or decreased)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F133872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Limbatril (DE);",
"     </li>",
"     <li>",
"      Limbatrilin (CN);",
"     </li>",
"     <li>",
"      Limbitrol (AE, AT, BE, BH, BR, CY, EG, FI, FR, GH, GR, ID, IL, IQ, IR, JO, KE, KW, LB, LY, NL, OM, QA, SA, SY, TW, TZ, UG, YE, ZM);",
"     </li>",
"     <li>",
"      Limbitryl (IT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F2572961\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F133868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/44/41671/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boakes AJ, Laurence DR, Teoh PC, et al, &ldquo;Interactions Between Sympathomimetic Amines and Antidepressant Agents in Man,&rdquo;",
"      <i>",
"       Br Med J",
"      </i>",
"      , 1973, 1(849):311-5.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jastak JT and Yagiela JA, &ldquo;Vasoconstrictors and Local Anesthesia: A Review and Rationale for Use,&rdquo;",
"      <i>",
"       J Am Dent Assoc",
"      </i>",
"      , 1983, 107(4):623-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/44/41671/abstract-text/6355236/pubmed\" id=\"6355236\" target=\"_blank\">",
"        6355236",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Larochelle P, Hamet P, and Enjalbert M, &ldquo;Responses to Tyramine and Norepinephrine After Imipramine and Trazodone,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1979, 26(1):24-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/44/41671/abstract-text/376211/pubmed\" id=\"376211\" target=\"_blank\">",
"        376211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mitchell JR, &ldquo;Guanethidine and Related Agents. III Antagonism by Drugs Which Inhibit the Norepinephrine Pump in Man,&rdquo;",
"      <i>",
"       J Clin Invest",
"      </i>",
"      , 1970, 49(8):1596-604.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/44/41671/abstract-text/5431666/pubmed\" id=\"5431666\" target=\"_blank\">",
"        5431666",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2003, 123(3):897-922.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/44/41671/abstract-text/12628894/pubmed\" id=\"12628894\" target=\"_blank\">",
"        12628894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pass SE and Simpson RW, &ldquo;Discontinuation and Reinstitution of Medications During the Perioperative Period,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2004, 61(9):899-912.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/44/41671/abstract-text/15156966/pubmed\" id=\"15156966\" target=\"_blank\">",
"        15156966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rundegren J, van Dijken J, M&ouml;rnstad H, et al, &ldquo;Oral Conditions in Patients Receiving Long-Term Treatment With Cyclic Antidepressant Drugs,&rdquo;",
"      <i>",
"       Swed Dent J",
"      </i>",
"      , 1985, 9(2):55-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/44/41671/abstract-text/3925584/pubmed\" id=\"3925584\" target=\"_blank\">",
"        3925584",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Svedmyr N, &ldquo;The Influence of a Tricyclic Antidepressive Agent (Protriptyline) on Some of the Circulatory Effects of Noradrenaline and Adrenalin in Man,&rdquo;",
"      <i>",
"       Life Sci",
"      </i>",
"      , 1968, 7(1):77-84.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8606 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-FD0A04FE88-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_44_41671=[""].join("\n");
var outline_f40_44_41671=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708614\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133889\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133879\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133880\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15671612\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15671613\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133864\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133852\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133891\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874547\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133866\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9954485\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133887\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133869\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133855\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133884\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133859\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14471180\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133882\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14471181\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133871\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4794408\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133872\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2572961\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133868\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8606\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8606|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?14/61/15317?source=related_link\">",
"      Amitriptyline and chlordiazepoxide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_44_41672="Molecular biology and physiology of estrogen action";
var content_f40_44_41672=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Molecular biology and physiology of estrogen action",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/44/41672/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/44/41672/contributors\">",
"     Sylvia Curtis Hewitt, MS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/44/41672/contributors\">",
"     Kenneth S Korach, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/44/41672/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/44/41672/contributors\">",
"     Peter J Snyder, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/44/41672/contributors\">",
"     William F Crowley, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/44/41672/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/44/41672/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/44/41672/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estrogens act most importantly on the reproductive organs, but they also act on other organ systems such as cardiovascular, skeletal, immune, gastrointestinal, and neural sites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41672/abstract/1\">",
"     1",
"    </a>",
"    ]. Their major actions are genomic, mediated by nuclear estrogen receptors, but they also have non-genomic actions. The molecular mechanisms of estrogen action will be reviewed here; the physiological actions of estrogens and estrogen analogues (selective estrogen receptor modulators) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/2/27685?source=see_link\">",
"     \"Physiology of the normal menstrual cycle\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/2/7210?source=see_link\">",
"     \"Mechanisms of action of selective estrogen receptor modulators\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/63/41975?source=see_link\">",
"     \"Estrogen and cognitive function\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ESTROGEN RECEPTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The genomic actions of estrogens are mediated via estrogen receptors, which are proteins that bind estrogens with high-affinity and specificity. These receptors are members of a family of nuclear hormone receptors that include receptors that bind other steroids, thyroid hormone, and retinoids, as well as many \"orphan\" receptors for which no ligands have been identified; all these receptors function as ligand-modulated nuclear transcription factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41672/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two estrogen receptor molecules have been identified: the original estrogen receptor alpha (ER-alpha), and the estrogen receptor beta (ER-beta) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41672/abstract/5\">",
"     5",
"    </a>",
"    ]. Their structures are similar to those of the other members of this family of receptors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41672/abstract/6\">",
"     6",
"    </a>",
"    ]. The key components are the C or DNA-binding domain, which binds with high affinity and specificity to DNA sequences (estrogen response elements) in the promoter regions of target genes, and the E or ligand-binding domain, which binds estrogens and estrogen analogues. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/2/7210?source=see_link\">",
"     \"Mechanisms of action of selective estrogen receptor modulators\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The consensus estrogen response element in the target genes is a 13-base pair inverted-repeat DNA sequence (GGTCAnnnTGACC), to which dimers of estrogen-estrogen receptor complexes bind with high affinity and specificity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41672/abstract/7\">",
"     7",
"    </a>",
"    ], with one receptor molecule in contact with each five base-pair segment of the response element [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41672/abstract/8\">",
"     8",
"    </a>",
"    ]. Dimerization of estrogen-estrogen receptor complexes is facilitated by receptor binding to a response element. Additional sequences located in the ligand-binding domain of the receptor also are involved in dimerization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41672/abstract/7\">",
"     7",
"    </a>",
"    ], as demonstrated by the formation of homodimers by truncated receptors containing only a ligand-binding domain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41672/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The estrogen receptors contain two regions, termed activation functions (AF), that mediate the increase in transcriptional activity induced by the receptors. AF-1, located toward the amino-terminal end of the receptor, acts independent of ligand, whereas AF-2, located in the ligand-binding domain, is ligand-dependent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41672/abstract/10\">",
"     10",
"    </a>",
"    ]. Numerous coregulator molecules, including an RNA molecule, that interact with estrogen receptors in a ligand-dependent manner have been isolated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41672/abstract/11-17\">",
"     11-17",
"    </a>",
"    ]. These coregulator molecules modulate receptor-mediated transcription by interacting with both the receptor AF sequences and molecules associated with RNA polymerase II [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41672/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When an estrogen or estrogen analogue reaches the cell nucleus and binds to an estrogen receptor, the conformation of the ligand-binding domain of the receptor is altered, allowing interaction with coactivator molecules if the ligand is an agonist, but preventing this interaction if the ligand is an antagonist [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41672/abstract/9,12,18\">",
"     9,12,18",
"    </a>",
"    ]. The estrogen receptor dimers bind to the response elements in target genes, and if agonist and coactivator are associated, induce transcription by interacting with and activating necessary components of the transcriptional apparatus. The presence of the active estrogen receptor-coactivator complex on the response sequence of target genes places this sequence in proximity to the RNA polymerase II transcription complex, allowing physical interaction and changes in the rate of transcription.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Alternative mechanisms of action",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the classic mechanism of estrogen receptor function, estrogen receptors can regulate expression of genes that lack an estrogen-response element. As an example, estrogen receptors can modulate the transcriptional activity of heterodimers of the transcription factors fos and jun, resulting in activation of genes containing AP-1 elements [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41672/abstract/19\">",
"     19",
"    </a>",
"    ]. In addition, complexes of estrogen receptors and SP1 molecules can activate some genes, such as those for c-FOS and transforming growth factor alpha, which lack a full estrogen-response element, by binding respectively to half sites of these response elements and GC-rich sequences in the regulatory regions of these genes (",
"    <a class=\"graphic graphic_figure graphicRef59162 \" href=\"mobipreview.htm?18/35/18992\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41672/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Estrogen receptors can also function independently of estrogen. Specifically, both epidermal growth factor and insulin-like growth factor-I, acting via their extracellular membrane bound receptors, can stimulate transcription of estrogen receptor target genes in the absence of estrogen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41672/abstract/22-28\">",
"     22-28",
"    </a>",
"    ]. Thus, cross-talk and signal amplification occurs between membrane-bound growth factor receptor pathways and nuclear receptors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41672/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     NONGENOMIC ACTIONS OF ESTROGENS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estrogens bind with high affinity to other cell components, including plasma membranes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41672/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. Some effects of estrogen, such as rapid induction of MAP kinase and Erk pathways, appear to involve direct action of estrogen receptors at the plasma membrane rather than genomic modulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41672/abstract/34-38\">",
"     34-38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As these rapid effects occur without ER-gene interaction, they are called \"non-genomic,\" although the signals initiated by these mechanisms ultimately result in regulation of genes. These responses are observed in diverse tissues, including the cardiovascular system, central nervous system, and in breast cancer cells. Several models have been developed that describe mechanisms for these non-genomic effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41672/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In some cases, the same ER molecule (ER alpha or ER beta) that interacts with genes in the nucleus becomes associated with the plasma membrane by interacting with membrane proteins such as caveolin, growth factor receptor binding proteins such as Shc, or with G proteins. Alternatively, a G protein coupled receptor, GPR30, may be activated at the membrane by estrogen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41672/abstract/41\">",
"     41",
"    </a>",
"    ]. The physiological significance of these rapid effects and how they are integrated with the nuclear responses to estrogen are important questions that are currently being investigated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PHYSIOLOGIC ROLES OF ESTROGENS: GENE TARGETED MODELS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanisms of estrogen receptor-mediated regulation of target genes have been extensively characterized using isolated cells or cell components. The ability to produce transgenic mice in which the estrogen receptor genes or the gene for aromatase, the enzyme that converts androgens to estrogens, have been knocked out [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41672/abstract/42-74\">",
"     42-74",
"    </a>",
"    ] and the identification of a limited number of patients with mutations in these genes has allowed study of the physiological processes that require estrogen in vivo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41672/abstract/75-77\">",
"     75-77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As might be expected, the most important defects in these patients (and in knockout models) are in the reproductive system. Both male and female mice lacking the estrogen receptor alpha gene or estrogen receptor alpha and beta genes are infertile, whereas in animals lacking only the estrogen receptor beta gene the males are fertile and the females are subfertile [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41672/abstract/42,54\">",
"     42,54",
"    </a>",
"    ]. Mice lacking the membrane G protein coupled receptor GPR30 are fertile, indicating this receptor is not necessary for reproductive function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41672/abstract/78\">",
"     78",
"    </a>",
"    ]. In mice lacking aromatase, the males are infertile and the females are anovulatory.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Female reproduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;In female mice, deletion of estrogen receptor alpha or aromatase results in complete infertility, and deletion of estrogen receptor beta results in subfertility, as a result of failure of several components necessary for successful reproduction. Normally, gonadotropin secretion by the pituitary is regulated by a negative feedback loop in which rising serum estrogen concentrations down-regulate transcription of the gene for the beta-subunit of luteinizing hormone (LH), and withdrawal of estrogen by ovariectomy results in an increase in LH secretion. Thus, mice with deletion of estrogen receptor alpha or aromatase and patients lacking aromatase or estrogen-receptor alpha have high serum LH concentrations. In contrast, serum LH concentrations are normal in estrogen receptor beta-deficient mice, indicating that the negative feedback is mediated by estrogen receptor alpha. Serum FSH levels in the estrogen receptor alpha deleted females are normal, and FSH increases in WT and estrogen receptor alpha deleted females following ovariectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41672/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Ovary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both estrogen receptor alpha and beta are present in normal mouse ovaries, but their distribution varies. Estrogen receptor beta is found predominantly in the granulosa cells of the follicles, whereas estrogen receptor alpha is found principally in the thecal and interstitial regions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41672/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ovaries of estrogen receptor alpha-deficient mice develop hemorrhagic cysts and lack mature follicles and corpora lutea, indicating the absence of ovulation, but they secrete increased amounts of estrogen and testosterone&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41672/abstract/42,64\">",
"     42,64",
"    </a>",
"    ], like the ovaries of transgenic mice that overexpress LH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41672/abstract/80\">",
"     80",
"    </a>",
"    ], indicating that the changes in the ovaries of the estrogen receptor alpha-deficient mice are due to LH hypersecretion. In support of this hypothesis, treatment of estrogen receptor alpha-deficient mice with a gonadotropin releasing-hormone antagonist decreases LH secretion and also prevents the ovaries from developing hemorrhagic cysts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41672/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Administration of gonadotropins to estrogen receptor alpha-deficient mice leads to formation of a few oocytes that can be fertilized in vitro, indicating that estrogen receptor alpha has a role in ovulation but is not required for oocyte development. This conclusion is also supported by studies in which developing follicles from wild type or estrogen receptor alpha deficient ovaries were cultured in vitro. Estrogen receptor alpha deficient follicles could be induced to ovulate at the same rate as wild type [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41672/abstract/82\">",
"     82",
"    </a>",
"    ]. This suggests that one cause of the more marked infertility in the estrogen receptor alpha-deficient mice is not intrinsic to the follicle but is the result of dysregulation of LH expression.",
"   </p>",
"   <p>",
"    The ovaries of mice with estrogen receptor beta deficiency are morphologically normal. Administration of gonadotropins to these animals also leads to formation of fewer oocytes than are produced by similarly treated wild-type mice, indicating a role for estrogen receptor beta in ovulation as well. When estrogen receptor beta deficient follicles were cultured in vitro, they grew normally until they reached the antral stage, at which time their growth was significantly diminished. In addition, their ovulation rate was significantly lower than that of WT follicles, indicating that in the case of estrogen receptor beta deficiency, the defect is intrinsic to the follicle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41672/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Uterus",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initiation and maintenance of pregnancy are dependent upon ovarian hormones. The pre-ovulatory peak of estrogen secretion is important for proliferation of the uterine epithelium in preparation for implantation, while rising progesterone secretion after ovulation is required for implantation of the embryo and the formation of decidual tissue in the stroma.",
"   </p>",
"   <p>",
"    The uterus of estrogen receptor alpha- and aromatase-deficient mice is hypoplastic, similar in appearance to the uterus in immature mice. In the former mice, the uterus does not respond to estrogen treatment in terms of weight increase, epithelial proliferation, or induction of estrogen-responsive genes, and therefore cannot support implantation of donor embryos [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41672/abstract/42,64\">",
"     42,64",
"    </a>",
"    ], whereas in aromatase-deficient mice the uterus is estrogen-responsive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41672/abstract/69\">",
"     69",
"    </a>",
"    ]. All of these responses are normal in estrogen receptor beta-deficient mice, and they can carry pregnancies to term [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41672/abstract/54\">",
"     54",
"    </a>",
"    ]. Thus, ovarian dysfunction is not the only component of infertility in estrogen receptor alpha-deficient mice.",
"   </p>",
"   <p>",
"    In contrast, inefficient ovarian function in estrogen receptor beta-deficient mice alone can explain the subfertility in these animals. Overall, it is apparent that estrogen receptor alpha is the receptor subtype required for uterine reproductive function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Mammary tissue",
"    </span>",
"    &nbsp;&mdash;&nbsp;At birth the mouse mammary gland consists of a rudimentary ductal tree, which, as female mice mature, elongates in response to estrogen and branches in response to progesterone to fill the stroma. In estrogen receptor alpha-deficient mice, the ductal rudiment fails to elongate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41672/abstract/50\">",
"     50",
"    </a>",
"    ]. In estrogen receptor beta-deficient mice the gland develops normally and these mice can nurse their young, indicating normal lactation function as well. These observations indicate that estrogen receptor alpha is required for normal mammary gland maturation and development. Clinical findings indicate estrogen plays a critical role in breast cancer, which led to the development of the selective estrogen antagonist,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    , as a chemotherapeutic agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41672/abstract/83\">",
"     83",
"    </a>",
"    ]. This topic is more extensively covered elsewhere.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Mating behavior",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another aspect of fertility requires neuroendocrine control of behavior. In this regard, the lack of estrogen receptor alpha also leads to severe disruption in female mating behavior, whereas the lack of estrogen receptor beta does not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41672/abstract/46,48\">",
"     46,48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Male reproduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Male mice with estrogen receptor alpha deficiency are infertile, demonstrating that estrogen has an essential role in male reproduction. The testes of these mice have dilated seminiferous tubules, due to lack of fluid resorption in the efferent ducts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41672/abstract/62,84\">",
"     62,84",
"    </a>",
"    ], and contain no sperm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41672/abstract/63\">",
"     63",
"    </a>",
"    ]. When germ cells from these mice are transplanted into the testes of normal mice depleted of germ cells, the recipients can produce normal offspring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41672/abstract/85,86\">",
"     85,86",
"    </a>",
"    ]. This observation indicates that estrogen receptor alpha is not needed for sperm function, but is required in the male reproductive tract to allow maturation of sperm. Similarly, aromatase-deficient mice are infertile due to loss of spermatids and epididymal sperm, but have normal fluid resorption in their efferent ducts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41672/abstract/72,73\">",
"     72,73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the lack of sperm alone results in male infertility, the mating behavior of mice with estrogen receptor alpha-, estrogen receptor alpha- and beta-, and aromatase deficiency is abnormal, while that of estrogen receptor beta-deficient mice is normal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41672/abstract/48\">",
"     48",
"    </a>",
"    ], indicating the importance of estrogen receptor alpha in normal male mating behavior.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Combined deficiency of estrogen receptor alpha and beta",
"    </span>",
"    &nbsp;&mdash;&nbsp;The phenotypes of mice with combined deficiency of estrogen receptor alpha and beta are similar to those of estrogen receptor alpha-deficient mice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41672/abstract/52\">",
"     52",
"    </a>",
"    ], emphasizing the importance of estrogen receptor alpha in both male and female reproduction. One exception is the appearance of the ovaries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41672/abstract/52\">",
"     52",
"    </a>",
"    ]. In mice with the combined deficiency, the ovaries contain some normal follicles, each containing an oocyte, and the granulosa cells and surrounding theca are normal. However, many follicles are abnormal, and when viewed in a two-dimensional section appear similar to seminiferous tubules. These follicles most often lack an oocyte and granulosa cells, but rather have Sertoli-like cells, located along the basement membrane. These latter changes emerge progressively with age, suggesting that these tubular structures represent \"ghosts\" of follicles in which the oocyte died and the remaining granulosa cells were \"trans-differentiated\" into Sertoli-like cells. These unusual follicles are an indication that both estrogen receptor alpha and beta are necessary to maintain normal follicular structures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Nonreproductive tissues",
"    </span>",
"    &nbsp;&mdash;&nbsp;The increased risk of osteoporosis and cardiovascular disease in postmenopausal women indicates a role for estrogen in bone and cardiovascular tissue. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/53/3929?source=see_link&amp;anchor=H15652976#H15652976\">",
"     \"Pathogenesis of osteoporosis\", section on 'Estrogen'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/36/29258?source=see_link\">",
"     \"Postmenopausal hormone therapy and cardiovascular risk\"",
"    </a>",
"    .) These tissues have been studied in estrogen receptor- and aromatase-deficient mice.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bone &mdash; The femurs of mice with estrogen receptor alpha and combined",
"      <span class=\"nowrap\">",
"       alpha/beta-deficiency,",
"      </span>",
"      but not estrogen receptor beta deficiency, are short [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/44/41672/abstract/87\">",
"       87",
"      </a>",
"      ] compared with those of normal mice, and mice with these deficiencies have lower serum IGF-1 concentrations. In addition, femoral diameter is smaller in affected female mice and femoral density is lower in affected male mice [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/44/41672/abstract/65\">",
"       65",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In estrogen receptor beta-deficient female mice, bone mineral content and density are increased, but they are normal in male mice [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/44/41672/abstract/88,89\">",
"       88,89",
"      </a>",
"      ], indicating that estrogen receptor beta may exert a negative effect on bone density in female mice. The major clinical problems in patients lacking aromatase or estrogen receptor alpha are osteoporosis or osteopenia and eunuchoid stature, due to lack of epiphyseal fusion, indicating the importance of estrogen in bone function in humans [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/44/41672/abstract/70\">",
"       70",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Blood vessels &mdash; The blood vessels of estrogen receptor-deficient mice have been evaluated by studying the protective effect of estrogen against carotid injury [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/44/41672/abstract/51,57,90\">",
"       51,57,90",
"      </a>",
"      ]. The protective effect was lost in estrogen receptor alpha deficient mice, but not in estrogen receptor beta-deficient mice [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/44/41672/abstract/91\">",
"       91",
"      </a>",
"      ], indicating estrogen receptor alpha mediates the estrogen protection on atherosclerosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/44/41672/abstract/92\">",
"       92",
"      </a>",
"      ]. The patient who lacked estrogen receptor alpha had endothelial dysfunction and evidence of coronary artery disease at age 31 years despite normal serum cholesterol concentrations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/44/41672/abstract/76\">",
"       76",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Gastrointestinal Tract &mdash; Cystic bowel disease and colon cancer are disease states more prevalent in men than in women [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/44/41672/abstract/93\">",
"       93",
"      </a>",
"      ]. In addition, postmenopausal hormone therapy reduces risk of colon cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/44/41672/abstract/94\">",
"       94",
"      </a>",
"      ]. Such findings suggest that estrogen protects colon health. Studies using the adenomatous polyposis coli (APC)",
"      <span class=\"nowrap\">",
"       Min/+",
"      </span>",
"      mouse, which bears a mutation in APC leading to intestinal adenomas, indicate that ovariectomy results in increased numbers of tumors, an effect that is reversed by estrogen replacement [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/44/41672/abstract/95\">",
"       95",
"      </a>",
"      ]. Studies in which ER alpha or ER beta deleted mice were crossed to the APC",
"      <span class=\"nowrap\">",
"       Min/+",
"      </span>",
"      mouse suggest the protective effects of estrogen are modulated by both estrogen receptors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/44/41672/abstract/96\">",
"       96",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Brain &mdash; The effects of estrogen on the brain and cognitive function are reviewed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/63/41975?source=see_link\">",
"       \"Estrogen and cognitive function\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Obesity and insulin resistance &mdash; Obesity and insulin resistance greatly impact human health. There is evidence from human as well as animal models for a protective role of estrogen. Diabetes is less prevalent in females than in males until after menopause and hormone therapy improves blood glucose control and insulin levels [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/44/41672/abstract/97,98\">",
"       97,98",
"      </a>",
"      ]. Additionally, studies in rodent models of insulin resistance or experimentally induced diabetes show sexually dimorphic patterns, with females often exhibiting reduced susceptibility, which is lost after ovariectomy. Estrogen treatment protects males and ovariectomized females [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/44/41672/abstract/98\">",
"       98",
"      </a>",
"      ]. In addition, mouse knockout models of ER-alpha or Cyp19, the enzyme that synthesizes E2, exhibit obesity and insulin resistance. Mice lacking alpha-ERKO are partially protected from experimentally induced diabetes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/44/41672/abstract/99\">",
"       99",
"      </a>",
"      ], suggesting not all the protective effects are mediated by ER-alpha. Men with mutations in Cyp19 or ER-alpha also exhibit insulin resistance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/44/41672/abstract/75,98\">",
"       75,98",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Estrogens act on the reproductive organs, cardiovascular organs, and bone. Their major actions are genomic, mediated by nuclear estrogen receptors, but they also have non-genomic actions.",
"     </li>",
"     <li>",
"      The genomic actions of estrogens are mediated via estrogen receptors, proteins that bind estrogens with high-affinity and specificity.",
"     </li>",
"     <li>",
"      Two estrogen receptor molecules have been identified: the original estrogen receptor alpha (ER-alpha), and the later described estrogen receptor beta (ER-beta). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Estrogen receptors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some effects of estrogen, such as rapid induction of MAP kinase, appear to involve direct action of estrogen receptors at the plasma membrane rather than genomic modulation.",
"     </li>",
"     <li>",
"      As these rapid effects occur without ER-gene interaction, they are called \"non-genomic,\" although the signals initiated by these mechanisms ultimately result in regulation of genes. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Nongenomic actions of estrogens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The ability to produce transgenic mice in which the estrogen receptor genes or the gene for aromatase, the enzyme that converts androgens to estrogens, have been knocked out and the identification of a limited number of patients with mutations in these genes, whose phenotypes closely assimilate each other, have allowed study of the physiological processes that require estrogen in vivo. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Physiologic roles of estrogens: Gene targeted models'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      As might be expected, the most important defects in these patients (and in knockout models) are in the reproductive system. Both male and female mice lacking the estrogen receptor alpha gene or estrogen receptor alpha and beta genes are infertile, whereas in animals lacking only the estrogen receptor beta gene the males are fertile and the females are subfertile. In mice lacking aromatase, the males are infertile and the females are anovulatory.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Selective estrogen receptor modulators (SERMs), such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    , as well as tissue selective estrogenic compounds (TSEC), such as",
"    <span class=\"nowrap\">",
"     bazedoxifene/conjugated",
"    </span>",
"    estrogen, are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/32/41481?source=see_link\">",
"     \"Selective estrogen receptor modulators for osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/1\">",
"      Deroo BJ, Korach KS. Estrogen receptors and human disease. J Clin Invest 2006; 116:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/2\">",
"      Mangelsdorf DJ, Thummel C, Beato M, et al. The nuclear receptor superfamily: the second decade. Cell 1995; 83:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/3\">",
"      Acevedo ML, Kraus WL. Transcriptional activation by nuclear receptors. Essays Biochem 2004; 40:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/4\">",
"      McEwan IJ. Sex, drugs and gene expression: signalling by members of the nuclear receptor superfamily. Essays Biochem 2004; 40:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/5\">",
"      Kuiper GG, Enmark E, Pelto-Huikko M, et al. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci U S A 1996; 93:5925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/6\">",
"      Tsai MJ, O'Malley BW. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem 1994; 63:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/7\">",
"      Glass CK. Differential recognition of target genes by nuclear receptor monomers, dimers, and heterodimers. Endocr Rev 1994; 15:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/8\">",
"      Klinge CM. Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res 2001; 29:2905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/9\">",
"      Pike AC, Brzozowski AM, Hubbard RE. A structural biologist's view of the oestrogen receptor. J Steroid Biochem Mol Biol 2000; 74:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/10\">",
"      Metzger D, Ali S, Bornert JM, Chambon P. Characterization of the amino-terminal transcriptional activation function of the human estrogen receptor in animal and yeast cells. J Biol Chem 1995; 270:9535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/11\">",
"      Hall JM, McDonnell DP. Coregulators in nuclear estrogen receptor action: from concept to therapeutic targeting. Mol Interv 2005; 5:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/12\">",
"      Edwards DP. The role of coactivators and corepressors in the biology and mechanism of action of steroid hormone receptors. J Mammary Gland Biol Neoplasia 2000; 5:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/13\">",
"      Parker MG. Transcriptional activation by oestrogen receptors. Biochem Soc Symp 1998; 63:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/14\">",
"      McKenna NJ, Lanz RB, O'Malley BW. Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev 1999; 20:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/15\">",
"      Lanz RB, McKenna NJ, Onate SA, et al. A steroid receptor coactivator, SRA, functions as an RNA and is present in an SRC-1 complex. Cell 1999; 97:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/16\">",
"      Endoh H, Maruyama K, Masuhiro Y, et al. Purification and identification of p68 RNA helicase acting as a transcriptional coactivator specific for the activation function 1 of human estrogen receptor alpha. Mol Cell Biol 1999; 19:5363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/17\">",
"      Watanabe M, Yanagisawa J, Kitagawa H, et al. A subfamily of RNA-binding DEAD-box proteins acts as an estrogen receptor alpha coactivator through the N-terminal activation domain (AF-1) with an RNA coactivator, SRA. EMBO J 2001; 20:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/18\">",
"      Hewitt SC, Harrell JC, Korach KS. Lessons in estrogen biology from knockout and transgenic animals. Annu Rev Physiol 2005; 67:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/19\">",
"      Kushner PJ, Agard DA, Greene GL, et al. Estrogen receptor pathways to AP-1. J Steroid Biochem Mol Biol 2000; 74:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/20\">",
"      Safe S, Kim K. Nuclear receptor-mediated transactivation through interaction with Sp proteins. Prog Nucleic Acid Res Mol Biol 2004; 77:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/21\">",
"      Safe, S. Transcriptional activation of genes by 17 beta-estradiol through estrogen receptor-Sp1 interactions. In: Vitamins and Hormones - Advances in Research and Applications 2001; 62:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/22\">",
"      Nelson KG, Takahashi T, Bossert NL, et al. Epidermal growth factor replaces estrogen in the stimulation of female genital-tract growth and differentiation. Proc Natl Acad Sci U S A 1991; 88:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/23\">",
"      Ignar-Trowbridge DM, Nelson KG, Bidwell MC, et al. Coupling of dual signaling pathways: epidermal growth factor action involves the estrogen receptor. Proc Natl Acad Sci U S A 1992; 89:4658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/24\">",
"      Ignar-Trowbridge DM, Teng CT, Ross KA, et al. Peptide growth factors elicit estrogen receptor-dependent transcriptional activation of an estrogen-responsive element. Mol Endocrinol 1993; 7:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/25\">",
"      Ignar-Trowbridge DM, Pimentel M, Teng CT, et al. Cross talk between peptide growth factor and estrogen receptor signaling systems. Environ Health Perspect 1995; 103 Suppl 7:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/26\">",
"      Ignar-Trowbridge DM, Pimentel M, Parker MG, et al. Peptide growth factor cross-talk with the estrogen receptor requires the A/B domain and occurs independently of protein kinase C or estradiol. Endocrinology 1996; 137:1735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/27\">",
"      Stoica A, Saceda M, Fakhro A, et al. Role of insulin-like growth factor-I in regulating estrogen receptor-alpha gene expression. J Cell Biochem 2000; 76:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/28\">",
"      Curtis SW, Washburn T, Sewall C, et al. Physiological coupling of growth factor and steroid receptor signaling pathways: estrogen receptor knockout mice lack estrogen-like response to epidermal growth factor. Proc Natl Acad Sci U S A 1996; 93:12626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/29\">",
"      Yee D, Lee AV. Crosstalk between the insulin-like growth factors and estrogens in breast cancer. J Mammary Gland Biol Neoplasia 2000; 5:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/30\">",
"      Cenni B, Picard D. Ligand-independent Activation of Steroid Receptors: New Roles for Old Players. Trends Endocrinol Metab 1999; 10:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/31\">",
"      Monje P, Boland R. Characterization of membrane estrogen binding proteins from rabbit uterus. Mol Cell Endocrinol 1999; 147:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/32\">",
"      Kelly MJ, Levin ER. Rapid actions of plasma membrane estrogen receptors. Trends Endocrinol Metab 2001; 12:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/33\">",
"      Levin ER. Nuclear receptor versus plasma membrane oestrogen receptor. Novartis Found Symp 2000; 230:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/34\">",
"      Coleman KM, Smith CL. Intracellular signaling pathways: nongenomic actions of estrogens and ligand-independent activation of estrogen receptors. Front Biosci 2001; 6:D1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/35\">",
"      Farhat MY, Abi-Younes S, Ramwell PW. Non-genomic effects of estrogen and the vessel wall. Biochem Pharmacol 1996; 51:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/36\">",
"      Gray GA, Sharif I, Webb DJ, Seckl JR. Oestrogen and the cardiovascular system: the good, the bad and the puzzling. Trends Pharmacol Sci 2001; 22:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/37\">",
"      Vasudevan N, Pfaff DW. Membrane-initiated actions of estrogens in neuroendocrinology: emerging principles. Endocr Rev 2007; 28:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/38\">",
"      Hewitt SC, Deroo BJ, Korach KS. Signal transduction. A new mediator for an old hormone? Science 2005; 307:1572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/39\">",
"      Levin ER, Pietras RJ. Estrogen receptors outside the nucleus in breast cancer. Breast Cancer Res Treat 2008; 108:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/40\">",
"      Pietras RJ, M&aacute;rquez-Garb&aacute;n DC. Membrane-associated estrogen receptor signaling pathways in human cancers. Clin Cancer Res 2007; 13:4672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/41\">",
"      Thomas P, Pang Y, Filardo EJ, Dong J. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology 2005; 146:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/42\">",
"      Lubahn DB, Moyer JS, Golding TS, et al. Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. Proc Natl Acad Sci U S A 1993; 90:11162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/43\">",
"      Ogawa S, Taylor JA, Lubahn DB, et al. Reversal of sex roles in genetic female mice by disruption of estrogen receptor gene. Neuroendocrinology 1996; 64:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/44\">",
"      Ogawa S, Lubahn DB, Korach KS, Pfaff DW. Aggressive behaviors of transgenic estrogen-receptor knockout male mice. Ann N Y Acad Sci 1996; 794:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/45\">",
"      Ogawa S, Lubahn DB, Korach KS, Pfaff DW. Behavioral effects of estrogen receptor gene disruption in male mice. Proc Natl Acad Sci U S A 1997; 94:1476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/46\">",
"      Ogawa S, Eng V, Taylor J, et al. Roles of estrogen receptor-alpha gene expression in reproduction-related behaviors in female mice. Endocrinology 1998; 139:5070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/47\">",
"      Ogawa S, Washburn TF, Taylor J, et al. Modifications of testosterone-dependent behaviors by estrogen receptor-alpha gene disruption in male mice. Endocrinology 1998; 139:5058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/48\">",
"      Ogawa S, Chan J, Chester AE, et al. Survival of reproductive behaviors in estrogen receptor beta gene-deficient (betaERKO) male and female mice. Proc Natl Acad Sci U S A 1999; 96:12887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/49\">",
"      Ogawa S, Chester AE, Hewitt SC, et al. Abolition of male sexual behaviors in mice lacking estrogen receptors alpha and beta (alpha beta ERKO). Proc Natl Acad Sci U S A 2000; 97:14737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/50\">",
"      Bocchinfuso WP, Lindzey JK, Hewitt SC, et al. Induction of mammary gland development in estrogen receptor-alpha knockout mice. Endocrinology 2000; 141:2982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/51\">",
"      Karas RH, Hodgin JB, Kwoun M, et al. Estrogen inhibits the vascular injury response in estrogen receptor beta-deficient female mice. Proc Natl Acad Sci U S A 1999; 96:15133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/52\">",
"      Couse JF, Hewitt SC, Bunch DO, et al. Postnatal sex reversal of the ovaries in mice lacking estrogen receptors alpha and beta. Science 1999; 286:2328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/53\">",
"      Schomberg DW, Couse JF, Mukherjee A, et al. Targeted disruption of the estrogen receptor-alpha gene in female mice: characterization of ovarian responses and phenotype in the adult. Endocrinology 1999; 140:2733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/54\">",
"      Krege JH, Hodgin JB, Couse JF, et al. Generation and reproductive phenotypes of mice lacking estrogen receptor beta. Proc Natl Acad Sci U S A 1998; 95:15677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/55\">",
"      Lindzey J, Wetsel WC, Couse JF, et al. Effects of castration and chronic steroid treatments on hypothalamic gonadotropin-releasing hormone content and pituitary gonadotropins in male wild-type and estrogen receptor-alpha knockout mice. Endocrinology 1998; 139:4092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/56\">",
"      Rissman EF, Early AH, Taylor JA, et al. Estrogen receptors are essential for female sexual receptivity. Endocrinology 1997; 138:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/57\">",
"      Iafrati MD, Karas RH, Aronovitz M, et al. Estrogen inhibits the vascular injury response in estrogen receptor alpha-deficient mice. Nat Med 1997; 3:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/58\">",
"      Rubanyi GM, Freay AD, Kauser K, et al. Vascular estrogen receptors and endothelium-derived nitric oxide production in the mouse aorta. Gender difference and effect of estrogen receptor gene disruption. J Clin Invest 1997; 99:2429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/59\">",
"      Scully KM, Gleiberman AS, Lindzey J, et al. Role of estrogen receptor-alpha in the anterior pituitary gland. Mol Endocrinol 1997; 11:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/60\">",
"      Johnson BD, Zheng W, Korach KS, et al. Increased expression of the cardiac L-type calcium channel in estrogen receptor-deficient mice. J Gen Physiol 1997; 110:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/61\">",
"      Freay AD, Curtis SW, Korach KS, Rubanyi GM. Mechanism of vascular smooth muscle relaxation by estrogen in depolarized rat and mouse aorta. Role of nuclear estrogen receptor and Ca2+ uptake. Circ Res 1997; 81:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/62\">",
"      Hess RA, Bunick D, Lee KH, et al. A role for oestrogens in the male reproductive system. Nature 1997; 390:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/63\">",
"      Eddy EM, Washburn TF, Bunch DO, et al. Targeted disruption of the estrogen receptor gene in male mice causes alteration of spermatogenesis and infertility. Endocrinology 1996; 137:4796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/64\">",
"      Couse JF, Curtis SW, Washburn TF, et al. Analysis of transcription and estrogen insensitivity in the female mouse after targeted disruption of the estrogen receptor gene. Mol Endocrinol 1995; 9:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/65\">",
"      Couse JF, Korach KS. Estrogen receptor null mice: what have we learned and where will they lead us? Endocr Rev 1999; 20:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/66\">",
"      Britt KL, Drummond AE, Cox VA, et al. An age-related ovarian phenotype in mice with targeted disruption of the Cyp 19 (aromatase) gene. Endocrinology 2000; 141:2614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/67\">",
"      Bulun SE. Aromatase deficiency and estrogen resistance: from molecular genetics to clinic. Semin Reprod Med 2000; 18:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/68\">",
"      Carani C, Qin K, Simoni M, et al. Effect of testosterone and estradiol in a man with aromatase deficiency. N Engl J Med 1997; 337:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/69\">",
"      Fisher CR, Graves KH, Parlow AF, Simpson ER. Characterization of mice deficient in aromatase (ArKO) because of targeted disruption of the cyp19 gene. Proc Natl Acad Sci U S A 1998; 95:6965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/70\">",
"      Grumbach MM, Auchus RJ. Estrogen: consequences and implications of human mutations in synthesis and action. J Clin Endocrinol Metab 1999; 84:4677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/71\">",
"      Oz OK, Zerwekh JE, Fisher C, et al. Bone has a sexually dimorphic response to aromatase deficiency. J Bone Miner Res 2000; 15:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/72\">",
"      Robertson KM, O'Donnell L, Jones ME, et al. Impairment of spermatogenesis in mice lacking a functional aromatase (cyp 19) gene. Proc Natl Acad Sci U S A 1999; 96:7986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/73\">",
"      Robertson KM, Simpson ER, Lacham-Kaplan O, Jones ME. Characterization of the fertility of male aromatase knockout mice. J Androl 2001; 22:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/74\">",
"      Simpson ER. Genetic mutations resulting in loss of aromatase activity in humans and mice. J Soc Gynecol Investig 2000; 7:S18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/75\">",
"      Smith EP, Boyd J, Frank GR, et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 1994; 331:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/76\">",
"      Sudhir K, Chou TM, Chatterjee K, et al. Premature coronary artery disease associated with a disruptive mutation in the estrogen receptor gene in a man. Circulation 1997; 96:3774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/77\">",
"      Sudhir K, Chou TM, Messina LM, et al. Endothelial dysfunction in a man with disruptive mutation in oestrogen-receptor gene. Lancet 1997; 349:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/78\">",
"      Otto C, Fuchs I, Kauselmann G, et al. GPR30 does not mediate estrogenic responses in reproductive organs in mice. Biol Reprod 2009; 80:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/79\">",
"      Lindzey J, Jayes FL, Yates MM, et al. The bi-modal effects of estradiol on gonadotropin synthesis and secretion in female mice are dependent on estrogen receptor-alpha. J Endocrinol 2006; 191:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/80\">",
"      Risma KA, Clay CM, Nett TM, et al. Targeted overexpression of luteinizing hormone in transgenic mice leads to infertility, polycystic ovaries, and ovarian tumors. Proc Natl Acad Sci U S A 1995; 92:1322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/81\">",
"      Couse JF, Bunch DO, Lindzey J, et al. Prevention of the polycystic ovarian phenotype and characterization of ovulatory capacity in the estrogen receptor-alpha knockout mouse. Endocrinology 1999; 140:5855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/82\">",
"      Emmen JM, Couse JF, Elmore SA, et al. In vitro growth and ovulation of follicles from ovaries of estrogen receptor (ER){alpha} and ER{beta} null mice indicate a role for ER{beta} in follicular maturation. Endocrinology 2005; 146:2817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/83\">",
"      Jordan VC. Chemoprevention of breast cancer with selective oestrogen-receptor modulators. Nat Rev Cancer 2007; 7:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/84\">",
"      Hess RA, Bunick D, Lubahn DB, et al. Morphologic changes in efferent ductules and epididymis in estrogen receptor-alpha knockout mice. J Androl 2000; 21:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/85\">",
"      Mahato D, Goulding EH, Korach KS, Eddy EM. Spermatogenic cells do not require estrogen receptor-alpha for development or function. Endocrinology 2000; 141:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/86\">",
"      Mahato D, Goulding EH, Korach KS, Eddy EM. Estrogen receptor-alpha is required by the supporting somatic cells for spermatogenesis. Mol Cell Endocrinol 2001; 178:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/87\">",
"      Vidal O, Lindberg MK, Hollberg K, et al. Estrogen receptor specificity in the regulation of skeletal growth and maturation in male mice. Proc Natl Acad Sci U S A 2000; 97:5474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/88\">",
"      Windahl SH, Vidal O, Andersson G, et al. Increased cortical bone mineral content but unchanged trabecular bone mineral density in female ERbeta(-/-) mice. J Clin Invest 1999; 104:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/89\">",
"      Windahl SH, Hollberg K, Vidal O, et al. Female estrogen receptor beta-/- mice are partially protected against age-related trabecular bone loss. J Bone Miner Res 2001; 16:1388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/90\">",
"      Karas RH, Schulten H, Pare G, et al. Effects of estrogen on the vascular injury response in estrogen receptor alpha, beta (double) knockout mice. Circ Res 2001; 89:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/91\">",
"      Pare G, Krust A, Karas RH, et al. Estrogen receptor-alpha mediates the protective effects of estrogen against vascular injury. Circ Res 2002; 90:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/92\">",
"      Hodgin JB, Krege JH, Reddick RL, et al. Estrogen receptor alpha is a major mediator of 17beta-estradiol's atheroprotective effects on lesion size in Apoe-/- mice. J Clin Invest 2001; 107:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/93\">",
"      Nelson RL, Dollear T, Freels S, Persky V. The relation of age, race, and gender to the subsite location of colorectal carcinoma. Cancer 1997; 80:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/94\">",
"      Grodstein F, Newcomb PA, Stampfer MJ. Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med 1999; 106:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/95\">",
"      Weyant MJ, Carothers AM, Mahmoud NN, et al. Reciprocal expression of ERalpha and ERbeta is associated with estrogen-mediated modulation of intestinal tumorigenesis. Cancer Res 2001; 61:2547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/96\">",
"      Cho NL, Javid SH, Carothers AM, et al. Estrogen receptors alpha and beta are inhibitory modifiers of Apc-dependent tumorigenesis in the proximal colon of Min/+ mice. Cancer Res 2007; 67:2366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/97\">",
"      Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/98\">",
"      Louet JF, LeMay C, Mauvais-Jarvis F. Antidiabetic actions of estrogen: insight from human and genetic mouse models. Curr Atheroscler Rep 2004; 6:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41672/abstract/99\">",
"      Le May C, Chu K, Hu M, et al. Estrogens protect pancreatic beta-cells from apoptosis and prevent insulin-deficient diabetes mellitus in mice. Proc Natl Acad Sci U S A 2006; 103:9232.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3803 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-C9EBEEE8B0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_44_41672=[""].join("\n");
var outline_f40_44_41672=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ESTROGEN RECEPTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Alternative mechanisms of action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      NONGENOMIC ACTIONS OF ESTROGENS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PHYSIOLOGIC ROLES OF ESTROGENS: GENE TARGETED MODELS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Female reproduction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Ovary",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Uterus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Mammary tissue",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Mating behavior",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Male reproduction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Combined deficiency of estrogen receptor alpha and beta",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Nonreproductive tissues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/3803\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/3803|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/35/18992\" title=\"figure 1\">",
"      ER Transcription",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/63/41975?source=related_link\">",
"      Estrogen and cognitive function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/2/7210?source=related_link\">",
"      Mechanisms of action of selective estrogen receptor modulators",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/53/3929?source=related_link\">",
"      Pathogenesis of osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/2/27685?source=related_link\">",
"      Physiology of the normal menstrual cycle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/36/29258?source=related_link\">",
"      Postmenopausal hormone therapy and cardiovascular risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/32/41481?source=related_link\">",
"      Selective estrogen receptor modulators for osteoporosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_44_41673="Rapid cycling bipolar disorder in adults: Treatment of mania, hypomania, and mixed episodes";
var content_f40_44_41673=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Rapid cycling bipolar disorder in adults: Treatment of mania, hypomania, and mixed episodes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/44/41673/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/44/41673/contributors\">",
"     Ralph Kupka, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/44/41673/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/44/41673/contributors\">",
"     Paul Keck, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/44/41673/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/44/41673/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/44/41673/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H12936951\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bipolar disorder is characterized by mood episodes that are nearly always recurrent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41673/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Patients who experience at least four episodes during a 12-month period are classified as &ldquo;rapid cycling&rdquo; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41673/abstract/1\">",
"     1",
"    </a>",
"    ]. The term was first used in 1974 to describe bipolar patients who were unresponsive to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41673/abstract/3\">",
"     3",
"    </a>",
"    ]. However, it is now clear that pharmacotherapy is often less beneficial for rapid cycling patients than non-rapid cycling patients, and that lithium may be as effective as other drugs for rapid cycling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41673/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic reviews the treatment of manic, hypomanic, and mixed episodes in rapid cycling patients. The treatment of major depression in rapid cycling patients, and the epidemiology, pathogenesis, clinical features, and diagnosis of rapid cycling in patients with bipolar disorder are discussed separately, as is the diagnosis and general treatment of bipolar disorder:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/14/42216?source=see_link\">",
"       \"Rapid cycling bipolar disorder in adults: Treatment of major depression\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/48/31497?source=see_link\">",
"       \"Rapid cycling bipolar disorder: Epidemiology, pathogenesis, clinical features, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19639?source=see_link\">",
"       \"Bipolar disorder in adults: Epidemiology and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/8/38026?source=see_link\">",
"       \"Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/3/44088?source=see_link\">",
"       \"Bipolar disorder in adults: Pharmacotherapy for acute depression\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/9/27802?source=see_link\">",
"       \"Bipolar disorder in adults: Maintenance treatment\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H81537125\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bipolar disorder is a mood disorder that is characterized by episodes of mania (",
"    <a class=\"graphic graphic_table graphicRef81976 \" href=\"mobipreview.htm?3/53/3932\">",
"     table 1",
"    </a>",
"    ), hypomania (",
"    <a class=\"graphic graphic_table graphicRef70757 \" href=\"mobipreview.htm?22/39/23164\">",
"     table 2",
"    </a>",
"    ), and major depression (",
"    <a class=\"graphic graphic_table graphicRef70852 \" href=\"mobipreview.htm?17/21/17756\">",
"     table 3",
"    </a>",
"    ), as well as mixed episodes (major depression concurrent with mania) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41673/abstract/1\">",
"     1",
"    </a>",
"    ]. The subtypes of bipolar disorder include bipolar I and bipolar II. Patients with bipolar I disorder experience manic and mixed episodes, and nearly always experience major depressive and hypomanic episodes. Bipolar II disorder is marked by at least one hypomanic episode, at least one major depressive episode, and the absence of manic and mixed episodes. Additional information about the clinical features and diagnosis of bipolar disorder is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19639?source=see_link&amp;anchor=H4#H4\">",
"     \"Bipolar disorder in adults: Epidemiology and diagnosis\", section on 'Clinical manifestations and diagnostic criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rapid cycling specifies a particular course of illness that can occur in bipolar I disorder or bipolar II disorder, rather than a subtype of bipolar disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41673/abstract/1\">",
"     1",
"    </a>",
"    ]. The diagnostic criteria for rapid cycling are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At least four mood episodes in a 12-month period",
"     </li>",
"     <li>",
"      The episodes meet both the symptom and duration criteria for a manic, hypomanic, major depressive, or mixed episode; the episodes that occur as part of a rapid cycling pattern are no different from episodes that occur as part of a non-rapid cycling pattern.",
"     </li>",
"     <li>",
"      The episodes are demarcated by a period of partial or full remission for at least two months, or by a switch to an episode of opposite polarity. Manic, hypomanic, and mixed episodes are counted as being on the same pole; thus, a switch in polarity involves one of these episodes and an episode of major depression.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional information about the clinical features and diagnosis of rapid cycling are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/48/31497?source=see_link\">",
"     \"Rapid cycling bipolar disorder: Epidemiology, pathogenesis, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86794887\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite clinical differences among manic, hypomanic, and mixed episodes, for the purpose of treatment they are considered to be similar and thus treated with the same medications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41673/abstract/5-7\">",
"     5-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Remission of a particular rapid cycling mood episode often occurs as a result of the course of illness, rather than treatment. Thus, the primary goal of treatment is to prevent further episodes.",
"   </p>",
"   <p>",
"    Response to pharmacotherapy appears to be poorer in rapid cycling bipolar disorder than non-rapid cycling bipolar disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41673/abstract/8-12\">",
"     8-12",
"    </a>",
"    ]. A meta-analysis of nine studies (primarily observational, 1424 bipolar patients) examined improvement of mood episodes and rates of recurrence in rapid cycling and non-rapid cycling patients, and found that an inferior response to medications was more probable in rapid cycling patients (risk ratio 1.4, 95% CI 1.3-1.6) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41673/abstract/4\">",
"     4",
"    </a>",
"    ]. Clinicians may find that it is not feasible for rapid cycling patients to fully remit from a mood episode or avoid recurrences [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41673/abstract/13\">",
"     13",
"    </a>",
"    ], and that a more realistic goal is to improve functioning and reduce the frequency, intensity, and duration of mood episodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41673/abstract/4\">",
"     4",
"    </a>",
"    ]. The difficulties posed by rapid cycling usually necessitate referral to a psychiatrist.",
"   </p>",
"   <p>",
"    The mood episodes that occur during rapid cycling are demarcated by a period of euthymia for at least two months, or by a switch from an episode of one polarity to an episode of the other polarity (eg, major depression to mania) without intervening euthymia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41673/abstract/14\">",
"     14",
"    </a>",
"    ]. Rapid cycling that is characterized by continuous switching between poles may respond more poorly to treatment than rapid cycling that includes intermittent periods of euthymia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41673/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Poor adherence to pharmacotherapy occurs in 20 to 40 percent of rapid cycling bipolar patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41673/abstract/17-19\">",
"     17-19",
"    </a>",
"    ], and appears to be more common in rapid cycling than non-rapid cycling patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41673/abstract/20\">",
"     20",
"    </a>",
"    ]. Nonadherence in bipolar disorder is often managed with psychoeducation, but this has not been studied in rapid cycling patients. Adherence to treatment and use of psychoeducation in bipolar disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/9/27802?source=see_link\">",
"     \"Bipolar disorder in adults: Maintenance treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2066405\">",
"    <span class=\"h2\">",
"     Monitoring the patient",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid cycling bipolar patients should be monitored for therapeutic and adverse medication effects, with particular attention to suicidal ideation and psychosis. The frequency of monitoring is determined by the patient&rsquo;s clinical status. Hospitalized patients are monitored daily. Outpatients are commonly seen on a weekly basis until they have responded (ie, the patient&rsquo;s safety has stabilized and the number, intensity, and frequency of psychotic and mood symptoms has improved substantially). Following response, patients can be seen every two to four weeks until they remit. Many authorities suggest that patients or caregivers record daily symptoms in a mood diary to help judge the effectiveness of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41673/abstract/10\">",
"     10",
"    </a>",
"    ]. However, this is not standard practice.",
"   </p>",
"   <p>",
"    For rapid cycling bipolar patients who remit and remain stable, monitoring can be tapered, with progressively longer intervals between assessments. As an example, a patient who is seen every two weeks at the time of remission can be seen every two weeks for one to three more visits, then every month for one to three visits, and then every two months for one to three visits. Continuously stable patients can ultimately be seen every three to six months. More frequent visits should be scheduled for patients who develop symptoms or side effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H289533874\">",
"    <span class=\"h2\">",
"     Duration of treatment trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;For rapid cycling bipolar patients, we suggest that clinicians try to prescribe a particular treatment regimen for at least two to four months before determining whether it effectively improves acute symptoms and reduces the frequency, intensity, and duration of recurrent mood episodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41673/abstract/10,12,21\">",
"     10,12,21",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6997118\">",
"    <span class=\"h1\">",
"     SEVERE EPISODES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe manic or mixed episodes are characterized by one or more of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Suicidal ideation or behavior",
"     </li>",
"     <li>",
"      Homicidal ideation or behavior",
"     </li>",
"     <li>",
"      Aggressive behavior",
"     </li>",
"     <li>",
"      Psychotic features (ie, delusions or hallucinations)",
"     </li>",
"     <li>",
"      Poor judgement that places the patient or others at imminent risk of being harmed (eg, impulsively moving across the country without any planning)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Severely ill patients generally require hospitalization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41673/abstract/5,6,22\">",
"     5,6,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For rapid cycling bipolar patients with severe manic or mixed episodes, we usually use a medication combination, which is consistent with the recommendation of treatment practice guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41673/abstract/5,6,22\">",
"     5,6,22",
"    </a>",
"    ] and many authorities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41673/abstract/8,10,14,21,23\">",
"     8,10,14,21,23",
"    </a>",
"    ]. Selecting a medication combination for treatment of severe manic and mixed episodes is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/8/38026?source=see_link&amp;anchor=H2269895045#H2269895045\">",
"     \"Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania\", section on 'First line medication combinations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For rapid cycling bipolar patients with severe manic or mixed episodes that do not respond to one medication combination, we suggest additional medication combination trials. Treatment of resistant patients is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/8/38026?source=see_link&amp;anchor=H7956384#H7956384\">",
"     \"Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania\", section on 'Resistant patients'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For rapid cycling bipolar patients with severe manic or mixed episodes that do not respond to four to six medication combinations, we suggest electroconvulsive therapy (ECT). Treatment of refractory patients is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/8/38026?source=see_link&amp;anchor=H7956632#H7956632\">",
"     \"Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania\", section on 'Refractory patients'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86794592\">",
"    <span class=\"h1\">",
"     MILD TO MODERATE EPISODES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild to moderate illness is marked by the absence of suicidal or homicidal ideation or behavior, aggressiveness, psychotic features, and poor judgement that places the patient or others at imminent risk of being harmed. Monotherapy is commonly used for initial treatment of rapid cycling patients with hypomania or mild to moderate manic or mixed episodes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86796256\">",
"    <span class=\"h2\">",
"     First line medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;For rapid cycling patients with hypomanic or mild to moderate manic or mixed episodes, we suggest",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/11/43193?source=see_link\">",
"     aripiprazole",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    monotherapy, based upon results from randomized trials for subgroups of rapid cycling patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41673/abstract/24-26\">",
"     24-26",
"    </a>",
"    ], as well as results for bipolar patients in general [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41673/abstract/27\">",
"     27",
"    </a>",
"    ]. We generally prefer risperidone and aripiprazole because they cause less weight gain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41673/abstract/28\">",
"     28",
"    </a>",
"    ]. Reasonable alternatives to risperidone, aripiprazole, or olanzapine include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    (see",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     \"Valproate: Drug information\"",
"    </a>",
"    ),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    , in order of preference. The doses, side effects, and pharmacology of these drugs are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/8/38026?source=see_link&amp;anchor=H244584#H244584\">",
"       \"Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania\", section on 'Medication doses and side effects'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/10/15530?source=see_link&amp;anchor=H76524637#H76524637\">",
"       \"Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\", section on 'Pharmacology'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43994?source=see_link\">",
"       \"Pharmacology of antiepileptic drugs\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/3/43065?source=see_link\">",
"       \"Bipolar disorder in adults and lithium: Pharmacology, administration, and side effects\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For rapid cycling bipolar patients who do not respond to treatment with one first-line medication, or do not tolerate the drug, we suggest tapering and discontinuing the failed medication over one to two weeks at the same time that another first-line medication is started and titrated up. (Response is defined as stabilization of the patient&rsquo;s safety and substantial improvement in the number, intensity, and frequency of psychotic and mood symptoms). The failed medication is generally tapered by the same amount for each dose decrease. As an example,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    4 mg per day is decreased by 1 to 2 mg per day, every one to two days.",
"   </p>",
"   <p>",
"    For rapid cycling patients with hypomanic or mild to moderate manic or mixed episodes, evidence for the efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/11/43193?source=see_link\">",
"     aripiprazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    includes the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"       Risperidone",
"      </a>",
"      &ndash; A three-week randomized trial compared risperidone (mean dose 4 mg per day) with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      (mean dose 15 mg per day) in patients with a manic or mixed episode [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/44/41673/abstract/26\">",
"       26",
"      </a>",
"      ]. In the subgroup with rapid cycling (N = 149), symptoms improved by approximately 60 percent with each drug, with no significant difference between the two medications; this was consistent with the finding that improvement with each drug was comparable in non-rapid cycling patients.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/11/43193?source=see_link\">",
"       Aripiprazole",
"      </a>",
"      &ndash; Two randomized trials, each lasting three weeks, compared aripiprazole (15 or 30 mg per day) with placebo in patients with a manic or mixed episode [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/44/41673/abstract/29,30\">",
"       29,30",
"      </a>",
"      ]. A pooled analysis found that in the subgroup with rapid cycling (N = 103), remission occurred in significantly more patients who received aripiprazole than placebo (48 versus 22 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/44/41673/abstract/24\">",
"       24",
"      </a>",
"      ]. This was consistent with the finding that aripiprazole was superior in the total sample.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"       Olanzapine",
"      </a>",
"      &ndash; Two randomized trials (three and four weeks in duration) compared olanzapine (5 to 20 mg per day) with placebo in patients with a manic or mixed episode [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/44/41673/abstract/31,32\">",
"       31,32",
"      </a>",
"      ]. A pooled analysis found that in the subgroup with rapid cycling (N = 90), response (improvement from baseline on the mania rating scale &ge; 50 percent) occurred in significantly more patients treated with olanzapine than placebo (75 versus 46 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/44/41673/abstract/25\">",
"       25",
"      </a>",
"      ]; this was consistent with the finding that olanzapine was superior in the total sample [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/44/41673/abstract/31,32\">",
"       31,32",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       Lithium",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A 20-month randomized trial compared",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      (mean serum concentration 0.9",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      with divalproex (mean serum concentration 77",
"      <span class=\"nowrap\">",
"       mcg/mL)",
"      </span>",
"      in 60 rapid cycling bipolar patients, who were initially stabilized for four weeks with open-label lithium plus divalproex [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/44/41673/abstract/17\">",
"       17",
"      </a>",
"      ]. Relapse was comparable in patients who received lithium or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      monotherapy (56 versus 50 percent), as was discontinuation due to adverse side effects (16 versus 4 percent).",
"     </li>",
"     <li>",
"      A review of eight studies (primarily open label) found that in 273 rapid cycling bipolar patients who were treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      for a mean of 50 months, the course of illness improved in 48 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/44/41673/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A pooled analysis of three observational studies found that in 172 rapid cycling bipolar patients who were treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      , recurrent mood episodes did not occur in 34 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/44/41673/abstract/33\">",
"       33",
"      </a>",
"      ]. In a separate pooled analysis of three observational studies with 90 rapid cycling patients who received lithium, the frequency, intensity, and duration of mood episodes decreased by 50 percent or more in 59 percent of patients. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"       Valproate",
"      </a>",
"      <strong>",
"       (divalproex)",
"      </strong>",
"      &ndash; A 47-week randomized trial compared divalproex (mean serum concentration 70",
"      <span class=\"nowrap\">",
"       mcg/mL)",
"      </span>",
"      with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      (5 to 20 mg per day) in patients with a manic or mixed episode [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/44/41673/abstract/34\">",
"       34",
"      </a>",
"      ]. In the subgroup with rapid cycling (N = 144), improvement from baseline with each drug was comparable. This was consistent with the finding in the total sample that remission was comparable for divalproex and olanzapine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/44/41673/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"       Quetiapine",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A prospective observational study of 16 rapid cycling bipolar patients who were treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      (target dose 150 to 200 mg per day, maximum 800 mg per day) for up to one year found that manic symptoms improved by at least 50 percent in eight of the patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/44/41673/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A prospective observational study of 5 rapid cycling bipolar patients who were treated with adjunctive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      (mean dose 720 mg per day) for a mean of four months found that the mean mania rating scale score decreased from baseline by approximately 60 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/44/41673/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"       Carbamazepine",
"      </a>",
"      &ndash; A review of 3 studies (primarily open label) found that in 133 rapid cycling bipolar patients who were treated with carbamazepine for a mean of 17 months, the course of illness improved in 45 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/44/41673/abstract/4\">",
"       4",
"      </a>",
"      ]. In addition, carbamazepine and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      were comparably effective in studies that directly compared the two treatments. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86796263\">",
"    <span class=\"h2\">",
"     Resistant patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon clinical experience, rapid cycling patients with hypomanic or mild to moderate manic or mixed episodes often do not respond to treatment with two to three sequential monotherapy trials with first-line medications. For these resistant patients, we suggest combining",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    with a second-generation antipsychotic (except",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    ), based upon meta-analyses of randomized trials that studied the general treatment of manic and mixed episodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/44/41673/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. The efficacy of medication combinations is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/8/38026?source=see_link&amp;anchor=H2269895045#H2269895045\">",
"     \"Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania\", section on 'First line medication combinations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We generally use a medication combination consisting of:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       Lithium",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"       risperidone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/11/43193?source=see_link\">",
"       aripiprazole",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      ; or",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"       Valproate",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"       risperidone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/11/43193?source=see_link\">",
"       aripiprazole",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, there is no high quality evidence of superior efficacy for any specific combination in treating rapid cycling patients with hypomanic or mild to moderate manic or mixed episodes. Reasonable alternatives to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/11/43193?source=see_link\">",
"     aripiprazole",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    or another first-generation antipsychotic,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/39/4728?source=see_link\">",
"     ziprasidone",
"    </a>",
"    . Selecting a combination is guided by past response to medications, the past response of family members with bipolar disorder to medications, specific symptoms, side effect profiles, potential drug-drug interactions, comorbid general medical conditions, patient preference, and cost. Specific medication interactions that can occur may be determined using the drug interactions tool (Lexi-Interact Online) included in UpToDate. This tool can be accessed from the UpToDate online search page or through the individual drug information topics in the section on Drug interactions.",
"   </p>",
"   <p>",
"    For resistant rapid cycling bipolar patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    monotherapy for hypomanic or mild to moderate manic or mixed episodes, we add",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/11/43193?source=see_link\">",
"     aripiprazole",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    to their regimen. For resistant patients receiving risperidone, aripiprazole, or olanzapine monotherapy, we add lithium or valproate to their regimen. The dose and side effects of lithium, valproate, risperidone, aripiprazole, and olanzapine are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/8/38026?source=see_link&amp;anchor=H244584#H244584\">",
"     \"Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania\", section on 'Medication doses and side effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Resistant rapid cycling bipolar patients who do not respond to or tolerate one medication combination should be treated with a second medication combination. Generally,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    is switched to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    or vice versa. As an example, for patients who do not respond to lithium plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/11/43193?source=see_link\">",
"     aripiprazole",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    , we suggest tapering and discontinuing lithium at the same time that valproate is started and titrated up. Lithium is generally tapered over one to two weeks by the same amount for each dose decrease (eg, lithium 1500 mg per day is decreased by 300 to 600 mg per day, every one to two days).",
"   </p>",
"   <p>",
"    Conversely, for resistant rapid cycling patients who do not respond to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/11/43193?source=see_link\">",
"     aripiprazole",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    , we suggest tapering and discontinuing valproate at the same time that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    is started and titrated up. Valproate is generally tapered over one to two weeks by the same amount for each dose decrease (eg, valproate 2000 mg per day is decreased by 250 to 500 mg per day, every one to two days).",
"   </p>",
"   <p>",
"    Although the antipsychotic (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/11/43193?source=see_link\">",
"     aripiprazole",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    ) is generally continued at the same dose when",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    is switched to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    or vice versa, it is also reasonable to switch the antipsychotic after lithium has been switched to valproate (or vice versa). The failed antipsychotic is generally tapered over one to two weeks by the same amount for each dose decrease (eg, risperidone 4 mg per day is decreased by 1 to 2 mg per day, every one to two days), and at the same time, the new antipsychotic is started and titrated up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86796271\">",
"    <span class=\"h2\">",
"     Refractory patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon clinical experience, rapid cycling bipolar patients with hypomania or mild to moderate mania or mixed episodes generally respond to sequential pharmacotherapy trials. For refractory patients who do not respond to four to eight medication combinations involving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    plus a second- or first-generation antipsychotic (not including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    ), we suggest either adding",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/43/41656?source=see_link\">",
"     levothyroxine",
"    </a>",
"    (T4) or using clozapine as monotherapy or add-on therapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/43/41656?source=see_link\">",
"       Levothyroxine",
"      </a>",
"      <strong>",
"       (T4)",
"      </strong>",
"      &ndash; For refractory rapid cycling bipolar patients with hypomanic or mild to moderate manic or mixed episodes, we suggest a trial of levothyroxine (T4) added to ongoing pharmacotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/44/41673/abstract/41\">",
"       41",
"      </a>",
"      ]. Prior to using T4, patients should be screened for contraindications such as hyperthyroidism, cardiac conditions, pregnancy and breastfeeding, osteoporosis in postmenopausal women, and dementia.",
"      <br/>",
"      <br/>",
"      In rapid cycling patients with a normal serum thyrotropin (TSH) concentration, T4 is started at 50 mcg per day, as a single morning dose approximately 30 minutes before breakfast. The dose is increased by increments of 50 mcg per day every week, to a target dose of 250 to 400 mcg per day, depending upon response and tolerability. The goal of treatment with supraphysiologic T4 doses is to increase serum T4 concentrations by 50 percent or more of baseline concentrations, which should result in a low TSH. In patients with subclinical or overt hypothyroidism, the dose should be started at 25 mcg per day and increased by 25 mcg per day every week, to the same target dose range.",
"      <br/>",
"      <br/>",
"      Evidence for the efficacy of adjunctive levothyroxine includes open-label treatment of 27 rapid cycling bipolar patients (described in single-case reports and three case series) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/44/41673/abstract/42\">",
"       42",
"      </a>",
"      ]. Levothyroxine was dosed between 50 to 500 mcg daily and given for 1 to 108 months. At least mild to moderate improvement occurred in 81 percent of the patients, and levothyroxine was usually well-tolerated. In addition, there was generally no relationship between baseline thyroid status and response [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/44/41673/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35161?source=see_link\">",
"       Clozapine",
"      </a>",
"      &ndash; Clozapine as monotherapy or augmentation is an alternative to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/43/41656?source=see_link\">",
"       levothyroxine",
"      </a>",
"      for refractory rapid cycling bipolar patients with hypomanic or mild to moderate manic or mixed episodes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/44/41673/abstract/44\">",
"       44",
"      </a>",
"      ]. We generally use clozapine as monotherapy if the existing medication regimen has provided little to no benefit or is poorly tolerated; clozapine is titrated up as the failed drugs are tapered and discontinued concurrently over one to two weeks. The failed drugs are usually decreased by the same amount for each dose decrease. The dose, side effects, and pharmacology of clozapine are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/40/6793?source=see_link\">",
"       \"Guidelines for prescribing clozapine in schizophrenia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/10/15530?source=see_link&amp;anchor=H76524735#H76524735\">",
"       \"Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\", section on 'Clozapine'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      For rapid cycling patients with refractory hypomanic or mild to moderate manic or mixed episodes, we generally use clozapine as augmentation if the existing medications have provided modest to moderate benefit and is well tolerated, and maintain the existing drugs at the same doses. However, if clozapine is added to a regimen that includes another second-generation antipsychotic, the failed antipsychotic is generally tapered over one to two weeks by the same amount for each dose decrease (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/11/43193?source=see_link\">",
"       aripiprazole",
"      </a>",
"      30 mg per day is decreased by 5 to 10 mg per day, every one to two days), and at the same time, clozapine is started and titrated up.",
"      <br/>",
"      <br/>",
"      Evidence for the efficacy of clozapine in treating refractory rapid cycling bipolar patients with hypomanic or mild to moderate manic or mixed episodes includes the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A one-year, open-label, randomized study compared",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35161?source=see_link\">",
"       clozapine",
"      </a>",
"      plus treatment as usual with treatment as usual in patients with treatment resistant bipolar disorder [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/44/41673/abstract/45\">",
"       45",
"      </a>",
"      ]; in the subgroup with rapid cycling (N = 15) who received adjunctive clozapine (mean dose 238 mg per day), more than 80 percent showed at least some improvement [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/44/41673/abstract/46\">",
"       46",
"      </a>",
"      ]. This was consistent with the finding that clozapine was beneficial in the total sample [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/44/41673/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A prospective observational study of 7 patients treated for 13 weeks with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35161?source=see_link\">",
"       clozapine",
"      </a>",
"      monotherapy (350 to 800 mg per day) found that mean scores on the mania rating scale decreased by more than 60 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/44/41673/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1370242\">",
"    <span class=\"h1\">",
"     MAINTENANCE TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend maintenance pharmacotherapy for rapid cycling bipolar patients with hypomanic or mild to moderate manic or mixed episodes that respond to treatment. Evidence for the efficacy of maintenance treatment includes the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 52-week, randomized maintenance trial compared",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"       risperidone",
"      </a>",
"      long-acting injectable (25 to 50 mg intramuscularly every two weeks) plus treatment as usual with placebo plus treatment as usual in 139 rapid cycling bipolar patients (who initially remitted with risperidone injectable plus treatment as usual) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/44/41673/abstract/11,48\">",
"       11,48",
"      </a>",
"      ]. Relapse of a mood episode occurred in significantly fewer patients who received adjunctive risperidone than placebo (22 versus 48 percent). In addition, discontinuation due to adverse events was comparable for risperidone and placebo (4 and 2 percent of patients).",
"     </li>",
"     <li>",
"      A 100-week, randomized maintenance trial compared",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/11/43193?source=see_link\">",
"       aripiprazole",
"      </a>",
"      (15 or 30 mg per day) with placebo in bipolar patients who were initially stabilized for at least six weeks with open-label aripiprazole [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/44/41673/abstract/49\">",
"       49",
"      </a>",
"      ]. In the subgroup with rapid cycling (N = 28), time to relapse was significantly longer with aripiprazole than placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/44/41673/abstract/50\">",
"       50",
"      </a>",
"      ]; this was consistent with the finding that aripiprazole was superior in the total sample [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/44/41673/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A 48-week, randomized maintenance trial compared",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      (5 to 20 mg per day) with placebo in bipolar patients who were initially stabilized for two weeks with open-label olanzapine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/44/41673/abstract/51\">",
"       51",
"      </a>",
"      ]. In the subgroup with rapid cycling (N = 179), time to recurrence of a mood episode was significantly longer with olanzapine than placebo. This was consistent with the finding that olanzapine was superior in the total sample.",
"     </li>",
"     <li>",
"      A 104-week, randomized maintenance trial compared",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      (mean dose 546 mg per day),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      (median serum concentration 0.63",
"      <span class=\"nowrap\">",
"       mEq/L),",
"      </span>",
"      and placebo in bipolar patients who were initially stabilized for four weeks with open-label quetiapine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/44/41673/abstract/52\">",
"       52",
"      </a>",
"      ]. In the subgroup with rapid cycling (N = 163), time to recurrence of a mood episode was significantly longer with quetiapine than placebo. Although the difference between lithium and placebo in rapid cycling patients was not significant, neither was the difference between quetiapine and lithium. Both quetiapine and lithium were superior to placebo in the total sample.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (See",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/5/4178?source=see_link\">",
"       \"Patient information: Bipolar disorder (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/21/6483?source=see_link\">",
"       \"Patient information: Reducing the costs of medicines (The Basics)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Beyond the Basics topics (See",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/55/39796?source=see_link\">",
"       \"Patient information: Bipolar disorder (manic depression) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/61/32726?source=see_link\">",
"       \"Patient information: Reducing the costs of medicines (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These educational materials can be used as part of psychoeducational psychotherapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/9/27802?source=see_link&amp;anchor=H21#H21\">",
"     \"Bipolar disorder in adults: Maintenance treatment\", section on 'Psychoeducation'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    The National Institute of Mental Health also has educational material explaining the symptoms, course of illness, and treatment of bipolar disorder in a booklet entitled \"Bipolar Disorder,\" which is available online at the website",
"    <a class=\"external\" href=\"file://www.nimh.nih.gov/health/publications/bipolar-disorder/complete-index.shtml\">",
"     file://www.nimh.nih.gov/health/publications/bipolar-disorder/complete-index.shtml",
"    </a>",
"    or through a toll-free number, 866-615-6464. The web site also provides references, summaries of study results in language intended for the lay public, and information about clinical trials currently recruiting patients.",
"   </p>",
"   <p>",
"    More comprehensive information is provided in many books written for patients and family members, including The Bipolar Disorder Survival Guide: What You and Your Family Need to Know, written by David J. Miklowitz, PhD (published by The Guilford Press, 2002); An Unquiet Mind: A Memoir of Moods and Madness, written by Kay Jamison, PhD (published by Random House, 1995); and Treatment of Bipolar Illness: A Casebook for Clinicians and Patients, by RM Post, MD, and GS Leverich, LCSW (published by Norton Press, 2008).",
"   </p>",
"   <p>",
"    The Depression and Bipolar Support Alliance (",
"    <a class=\"external\" href=\"file://www.dbsalliance.org/\">",
"     file://www.dbsalliance.org",
"    </a>",
"    or 800-826-3632) is a national organization that educates members about bipolar disorder and how to cope with it. Other functions include increasing public awareness of the illness and advocating for more research and services. The organization is administered and maintained by patients and family members, and has local chapters.",
"   </p>",
"   <p>",
"    The National Alliance on Mental Illness (",
"    <a class=\"external\" href=\"file://www.nami.org/\">",
"     file://www.nami.org",
"    </a>",
"    or 800-950-6264) is a similarly structured organization devoted to education, support, and advocacy for patients with any mental illness. Bipolar disorder is one of their priorities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86795525\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bipolar disorder is characterized by episodes of mania (",
"      <a class=\"graphic graphic_table graphicRef81976 \" href=\"mobipreview.htm?3/53/3932\">",
"       table 1",
"      </a>",
"      ), hypomania (",
"      <a class=\"graphic graphic_table graphicRef70757 \" href=\"mobipreview.htm?22/39/23164\">",
"       table 2",
"      </a>",
"      ), and major depression (",
"      <a class=\"graphic graphic_table graphicRef70852 \" href=\"mobipreview.htm?17/21/17756\">",
"       table 3",
"      </a>",
"      ), as well as mixed episodes (major depression concurrent with mania or hypomania). (See",
"      <a class=\"local\" href=\"#H81537125\">",
"       'Definitions'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19639?source=see_link&amp;anchor=H4#H4\">",
"       \"Bipolar disorder in adults: Epidemiology and diagnosis\", section on 'Clinical manifestations and diagnostic criteria'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rapid cycling bipolar disorder is diagnosed in patients with four or more mood episodes during a 12-month period. The episodes that occur during rapid cycling are no different from episodes that occur as part of a non-rapid cycling pattern. Separate episodes are demarcated from each other either by a switch from one pole to the other (eg, major depression to mania), or by full or partial remission for at least two months. (See",
"      <a class=\"local\" href=\"#H81537125\">",
"       'Definitions'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/48/31497?source=see_link&amp;anchor=H16495348#H16495348\">",
"       \"Rapid cycling bipolar disorder: Epidemiology, pathogenesis, clinical features, and diagnosis\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Remission of a particular rapid cycling mood episode often occurs as a result of the course of illness, rather than treatment. Thus, the primary goal of treatment is to prevent further episodes. (See",
"      <a class=\"local\" href=\"#H86794887\">",
"       'General principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For rapid cycling bipolar patients with severe manic or mixed episodes, we suggest initial treatment with a medication combination rather than monotherapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6997118\">",
"       'Severe episodes'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/8/38026?source=see_link&amp;anchor=H2269895045#H2269895045\">",
"       \"Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania\", section on 'First line medication combinations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For resistant rapid cycling bipolar patients with severe manic or mixed episodes that do not respond to one medication combination, we suggest additional medication combination trials rather than electroconvulsive therapy (ECT) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6997118\">",
"       'Severe episodes'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/8/38026?source=see_link&amp;anchor=H7956384#H7956384\">",
"       \"Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania\", section on 'Resistant patients'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For treatment refractory patients with severe manic or mixed episodes that do not respond to four to six medication combinations, we suggest ECT rather than additional trials of medication combinations (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6997118\">",
"       'Severe episodes'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/8/38026?source=see_link&amp;anchor=H7956632#H7956632\">",
"       \"Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania\", section on 'Refractory patients'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For rapid cycling bipolar patients with hypomanic or mild to moderate manic or mixed episodes, we suggest initial treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"       risperidone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/11/43193?source=see_link\">",
"       aripiprazole",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      monotherapy, rather than other medications (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We prefer risperidone and aripiprazole because they cause less weight gain. Reasonable alternatives to risperidone, aripiprazole, or olanzapine include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H86796256\">",
"       'First line medications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For resistant rapid cycling bipolar patients with hypomanic or mild to moderate manic or mixed episodes that do not respond to treatment with two to three sequential monotherapy trials, we suggest combining",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"       risperidone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/11/43193?source=see_link\">",
"       aripiprazole",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      rather than additional monotherapy trials (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However, reasonable alternatives include lithium or valproate plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"       haloperidol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/39/4728?source=see_link\">",
"       ziprasidone",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H86796263\">",
"       'Resistant patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For refractory rapid cycling bipolar patients with hypomanic or mild to moderate manic or mixed episodes that do not respond to treatment with four to eight medication combinations, we suggest adding",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/43/41656?source=see_link\">",
"       levothyroxine",
"      </a>",
"      rather than other medications (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35161?source=see_link\">",
"       clozapine",
"      </a>",
"      as monotherapy or augmentation is a reasonable alternative. (See",
"      <a class=\"local\" href=\"#H86796271\">",
"       'Refractory patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For rapid cycling bipolar patients with hypomanic or mild to moderate manic or mixed episodes that respond to treatment, we recommend maintenance pharmacotherapy rather than no treatment (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1370242\">",
"       'Maintenance treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, American Psychiatric Association, Washington, DC, 2000.",
"    </li>",
"    <li>",
"     Goodwin FK, Jamison KR. Manic-Depressive Illness: Bipolar Disorders and Recurrent Depression, Second Edition, Oxford University Press, Oxford 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41673/abstract/3\">",
"      Dunner DL, Fieve RR. Clinical factors in lithium carbonate prophylaxis failure. Arch Gen Psychiatry 1974; 30:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41673/abstract/4\">",
"      Tondo L, Hennen J, Baldessarini RJ. Rapid-cycling bipolar disorder: effects of long-term treatments. Acta Psychiatr Scand 2003; 108:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41673/abstract/5\">",
"      Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. World J Biol Psychiatry 2009; 10:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41673/abstract/6\">",
"      American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002; 159:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41673/abstract/7\">",
"      Yatham LN, Kennedy SH, O'Donovan C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord 2005; 7 Suppl 3:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41673/abstract/8\">",
"      Bauer M, Beaulieu S, Dunner DL, et al. Rapid cycling bipolar disorder--diagnostic concepts. Bipolar Disord 2008; 10:153.",
"     </a>",
"    </li>",
"    <li>",
"     Kupka RW, Frye MA. Diagnosis and treatment of rapid cycling bipolar disorder. In: Yatham L, Kusumakar V (Ed.) Bipolar Disorder. A clinician&rsquo;s guide to biological treatments, 2nd Ed. New York, Brunner-Routledge, 2009.",
"    </li>",
"    <li>",
"     National Institute for Health and Clinical Excellence. Bipolar disorder: The management of bipolar disorder in adults, children and adolescents, in primary and secondary care.",
"National Clinical Practice Guideline Number 38, 2006. file://www.nice.org.uk/ (Accessed on April 26, 2011).",
"    </li>",
"    <li>",
"     Ketter TA, Wang PW. Management of rapid-cycling bipolar disorders. In: Handbook of Diagnosis and Treatment of Bipolar Disorders, Ketter TA.  (Ed), American Psychiatric Publishing, Inc, Washington, DC 2010. p.331.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41673/abstract/12\">",
"      Schneck CD. Treatment of rapid-cycling bipolar disorder. J Clin Psychiatry 2006; 67 Suppl 11:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41673/abstract/13\">",
"      Schneck CD, Miklowitz DJ, Miyahara S, et al. The prospective course of rapid-cycling bipolar disorder: findings from the STEP-BD. Am J Psychiatry 2008; 165:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41673/abstract/14\">",
"      Goodwin GM, Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2009; 23:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41673/abstract/15\">",
"      Maj M, Pirozzi R, Magliano L, Bartoli L. The prognostic significance of \"switching\" in patients with bipolar disorder: a 10-year prospective follow-up study. Am J Psychiatry 2002; 159:1711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41673/abstract/16\">",
"      Maj M, Pirozzi R, Formicola AM, Tortorella A. Reliability and validity of four alternative definitions of rapid-cycling bipolar disorder. Am J Psychiatry 1999; 156:1421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41673/abstract/17\">",
"      Calabrese JR, Shelton MD, Rapport DJ, et al. A 20-month, double-blind, maintenance trial of lithium versus divalproex in rapid-cycling bipolar disorder. Am J Psychiatry 2005; 162:2152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41673/abstract/18\">",
"      Sajatovic M, Elhaj O, Youngstrom EA, et al. Treatment adherence in individuals with rapid cycling bipolar disorder: results from a clinical-trial setting. J Clin Psychopharmacol 2007; 27:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41673/abstract/19\">",
"      Kemp DE, Gao K, Ganocy SJ, et al. A 6-month, double-blind, maintenance trial of lithium monotherapy versus the combination of lithium and divalproex for rapid-cycling bipolar disorder and Co-occurring substance abuse or dependence. J Clin Psychiatry 2009; 70:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41673/abstract/20\">",
"      Perlis RH, Ostacher MJ, Miklowitz DJ, et al. Clinical features associated with poor pharmacologic adherence in bipolar disorder: results from the STEP-BD study. J Clin Psychiatry 2010; 71:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41673/abstract/21\">",
"      Coryell W. Rapid cycling bipolar disorder: clinical characteristics and treatment options. CNS Drugs 2005; 19:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41673/abstract/22\">",
"      Yatham LN, Kennedy SH, Schaffer A, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord 2009; 11:225.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association Practice Guideline for Treatment of Patients with Bipolar Disorder (Revision), 2002 file://www.psych.org/MainMenu/PsychiatricPractice/PracticeGuidelines_1.aspx (Accessed on April 25, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41673/abstract/24\">",
"      Suppes T, Eudicone J, McQuade R, et al. Efficacy and safety of aripiprazole in subpopulations with acute manic or mixed episodes of bipolar I disorder. J Affect Disord 2008; 107:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41673/abstract/25\">",
"      Baldessarini RJ, Hennen J, Wilson M, et al. Olanzapine versus placebo in acute mania: treatment responses in subgroups. J Clin Psychopharmacol 2003; 23:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41673/abstract/26\">",
"      Perlis RH, Baker RW, Zarate CA Jr, et al. Olanzapine versus risperidone in the treatment of manic or mixed States in bipolar I disorder: a randomized, double-blind trial. J Clin Psychiatry 2006; 67:1747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41673/abstract/27\">",
"      Cipriani A, Barbui C, Salanti G, et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet 2011; 378:1306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41673/abstract/28\">",
"      Raedler TJ. Cardiovascular aspects of antipsychotics. Curr Opin Psychiatry 2010; 23:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41673/abstract/29\">",
"      Keck PE Jr, Marcus R, Tourkodimitris S, et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003; 160:1651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41673/abstract/30\">",
"      Sachs G, Sanchez R, Marcus R, et al. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol 2006; 20:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41673/abstract/31\">",
"      Tohen M, Sanger TM, McElroy SL, et al. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am J Psychiatry 1999; 156:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41673/abstract/32\">",
"      Tohen M, Jacobs TG, Grundy SL, et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group. Arch Gen Psychiatry 2000; 57:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41673/abstract/33\">",
"      Kupka RW, Luckenbaugh DA, Post RM, et al. Rapid and non-rapid cycling bipolar disorder: a meta-analysis of clinical studies. J Clin Psychiatry 2003; 64:1483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41673/abstract/34\">",
"      Tohen M, Ketter TA, Zarate CA, et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry 2003; 160:1263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41673/abstract/35\">",
"      Suppes T, Brown E, Schuh LM, et al. Rapid versus non-rapid cycling as a predictor of response to olanzapine and divalproex sodium for bipolar mania and maintenance of remission: post hoc analyses of 47-week data. J Affect Disord 2005; 89:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41673/abstract/36\">",
"      Goldberg JF, Kelley ME, Rosenquist KJ, et al. Effectiveness of quetiapine in rapid cycling bipolar disorder: a preliminary study. J Affect Disord 2008; 105:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41673/abstract/37\">",
"      Vieta E, Parramon G, Padrell E, et al. Quetiapine in the treatment of rapid cycling bipolar disorder. Bipolar Disord 2002; 4:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41673/abstract/38\">",
"      Scherk H, Pajonk FG, Leucht S. Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials. Arch Gen Psychiatry 2007; 64:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41673/abstract/39\">",
"      Perlis RH, Welge JA, Vornik LA, et al. Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials. J Clin Psychiatry 2006; 67:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41673/abstract/40\">",
"      Smith LA, Cornelius V, Warnock A, et al. Acute bipolar mania: a systematic review and meta-analysis of co-therapy vs. monotherapy. Acta Psychiatr Scand 2007; 115:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41673/abstract/41\">",
"      Bauer M, Bergh&ouml;fer A, Bschor T, et al. Supraphysiological doses of L-thyroxine in the maintenance treatment of prophylaxis-resistant affective disorders. Neuropsychopharmacology 2002; 27:620.",
"     </a>",
"    </li>",
"    <li>",
"     Kupka RW. Treatment options for rapid cycling bipolar disorder. Clinical Approaches in Bipolar Disorders, 2006; 5: 22-29.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41673/abstract/43\">",
"      Bauer MS, Whybrow PC. Rapid cycling bipolar affective disorder. II. Treatment of refractory rapid cycling with high-dose levothyroxine: a preliminary study. Arch Gen Psychiatry 1990; 47:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41673/abstract/44\">",
"      Frye MA, Altshuler LL, Bitran JA. Clozapine in rapid cycling bipolar disorder. J Clin Psychopharmacol 1996; 16:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41673/abstract/45\">",
"      Suppes T, Webb A, Paul B, et al. Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. Am J Psychiatry 1999; 156:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41673/abstract/46\">",
"      Suppes T, Ozcan ME, Carmody T. Response to clozapine of rapid cycling versus non-cycling patients with a history of mania. Bipolar Disord 2004; 6:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41673/abstract/47\">",
"      Calabrese JR, Kimmel SE, Woyshville MJ, et al. Clozapine for treatment-refractory mania. Am J Psychiatry 1996; 153:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41673/abstract/48\">",
"      Macfadden W, Haskins T, Kujawa M, et al. Adjunctive risperidone long-acting injectable is effective in delaying relapse to a mood episode in patients with frequently relapsing bipolar disorder (abstract 584). Biol Psychiatry 2008; 63 (suppl):186S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41673/abstract/49\">",
"      Keck PE Jr, Calabrese JR, McIntyre RS, et al. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry 2007; 68:1480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41673/abstract/50\">",
"      Muzina DJ, Momah C, Eudicone JM, et al. Aripiprazole monotherapy in patients with rapid-cycling bipolar I disorder: an analysis from a long-term, double-blind, placebo-controlled study. Int J Clin Pract 2008; 62:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41673/abstract/51\">",
"      Tohen M, Calabrese JR, Sachs GS, et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry 2006; 163:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/44/41673/abstract/52\">",
"      Weisler RH, Nolen WA, Neijber A, et al. Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study). J Clin Psychiatry 2011; 72:1452.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16847 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-F656983DA9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_44_41673=[""].join("\n");
var outline_f40_44_41673=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H86795525\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12936951\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H81537125\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H86794887\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2066405\">",
"      Monitoring the patient",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H289533874\">",
"      Duration of treatment trial",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6997118\">",
"      SEVERE EPISODES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H86794592\">",
"      MILD TO MODERATE EPISODES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86796256\">",
"      First line medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86796263\">",
"      Resistant patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86796271\">",
"      Refractory patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1370242\">",
"      MAINTENANCE TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H86795525\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/16847\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/16847|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/53/3932\" title=\"table 1\">",
"      DSM-IV-TR diagnostic criteria for mania",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/39/23164\" title=\"table 2\">",
"      DSM-IV-TR diagnostic criteria for hypomania",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/21/17756\" title=\"table 3\">",
"      DSM-IV-TR diagnostic criteria for major depression",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/3/43065?source=related_link\">",
"      Bipolar disorder in adults and lithium: Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19639?source=related_link\">",
"      Bipolar disorder in adults: Epidemiology and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/9/27802?source=related_link\">",
"      Bipolar disorder in adults: Maintenance treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/3/44088?source=related_link\">",
"      Bipolar disorder in adults: Pharmacotherapy for acute depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/8/38026?source=related_link\">",
"      Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/40/6793?source=related_link\">",
"      Guidelines for prescribing clozapine in schizophrenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/5/4178?source=related_link\">",
"      Patient information: Bipolar disorder (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/55/39796?source=related_link\">",
"      Patient information: Bipolar disorder (manic depression) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/61/32726?source=related_link\">",
"      Patient information: Reducing the costs of medicines (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/21/6483?source=related_link\">",
"      Patient information: Reducing the costs of medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43994?source=related_link\">",
"      Pharmacology of antiepileptic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/14/42216?source=related_link\">",
"      Rapid cycling bipolar disorder in adults: Treatment of major depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/48/31497?source=related_link\">",
"      Rapid cycling bipolar disorder: Epidemiology, pathogenesis, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/10/15530?source=related_link\">",
"      Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=related_link\">",
"      Valproate: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_44_41674="Patho nerve sheath A";
var content_f40_44_41674=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F51535%7EONC%2F58208%7EONC%2F71091&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F51535%7EONC%2F58208%7EONC%2F71091&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Intradural nerve sheath tumor: Alternating compact Antoni A areas traversed by a vertical band of looser Antoni B tissue",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 351px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Intradural nerve sheath tumor: Antoni A (upper right) and B (lower left)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 351px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Intradural nerve sheath tumor: Wavy spindle cells that may be seen in schwannoma or neurofibroma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 351px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_44_41674=[""].join("\n");
var outline_f40_44_41674=null;
var title_f40_44_41675="Diseases related to infertility";
var content_f40_44_41675=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F80115&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F80115&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Frequency of diseases associated with infertility",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"        <br/>",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\">",
"        Percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Female partner",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ovulatory disorders",
"       </td>",
"       <td colspan=\"1\">",
"        25 to 27",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Endometriosis",
"       </td>",
"       <td colspan=\"1\">",
"        5 to 15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pelvic adhesions",
"       </td>",
"       <td colspan=\"1\">",
"        12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tubal occlusion",
"       </td>",
"       <td colspan=\"1\">",
"        11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Other tubal abnormalities",
"       </td>",
"       <td colspan=\"1\">",
"        11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hyperprolactinemia",
"       </td>",
"       <td>",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Male partner",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Abnormal semen analysis",
"       </td>",
"       <td colspan=\"1\">",
"        25",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Unexplained",
"       </td>",
"       <td>",
"        17",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Other",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from data in WHO Scientific Group Report. Recent Advances in Medically Assisted Conception. WHO Technical Report Series 820. Geneva. World Health Organization 1992 and Collins, JA. Unexplained Infertility. In Keye WR, Chang RJ, Rebar RW, Soules MR (eds). Infertility: evaluation and treatment. WB Saunders, Philadelphia 1999, p 249.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_44_41675=[""].join("\n");
var outline_f40_44_41675=null;
var title_f40_44_41676="ACC AHA bridging therapy";
var content_f40_44_41676=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F56682&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F56682&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA Guideline Summary: Bridging therapy in patients with mechanical valves who require interruption of warfarin therapy for noncardiac surgery, invasive procedures, or dental care",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class I - There is evidence and/or general agreement that the following approach to bridging therapy is effective in patients with mechanical valves",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        &bull; Among patients who are at low risk for thrombosis, which is defined as a bileaflet aortic valve with no risk factors*.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1. Warfarin should be withheld 48 to 72 hours before the procedure to allow the INR to fall below 1.5.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2. Warfarin is restarted 24 hours after the procedure.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        3. Heparin is usually not necessary.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        &bull; Among patients who are at high risk for thrombosis, which is defined as a mechanical aortic valve with any risk factor* or any mechanical mitral valve.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1. Warfarin should be withheld more than 72 hours before the procedure.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2. Therapeutic doses of intravenous unfractionated heparin should be started when the INR falls below 2.0 (usually 48 hours before the procedure).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        3. Heparin is stopped four to six hours before the procedure.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        4. Heparin and warfarin are restarted as soon after surgery as bleeding stability permits.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        5. Heparin is discontinued when the INR reaches therapeutic levels.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIa - The weight of evidence or opinion is in favor of the usefulness of the following approach to bridging therapy in patients with mechanical valves",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; The administration of fresh frozen plasma when an emergency procedure is necessary. Fresh frozen plasma is preferred in this setting to high dose vitamin K1.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIb - The weight of evidence or opinion is less well established for the following approach to bridging therapy in patients with mechanical valves",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Among patients at high risk for thrombosis as defined above, therapeutic doses of unfractionated heparin (15,000 units every 12 hours) or low molecular weight heparin (100 U/kg every 12 hours) during the period when the INR is subtherapeutic.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class III - There is evidence and/or general agreement that the following approach to bridging therapy is NOT useful in patients with mechanical valves",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Routine high dose vitamin K1, which can cause a hypercoagulable state.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Risk factors include atrial fibrillation, previous thromboembolism, left ventricular dysfunction, a hypercoagulable state, older generation thrombogenic valves, a mechanical tricuspid valve, or multiple valves.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Circulation 2008; 118:e523.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_44_41676=[""].join("\n");
var outline_f40_44_41676=null;
var title_f40_44_41677="Contents: Infection control";
var content_f40_44_41677=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?15/21/15710\">",
"       Infectious Diseases",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Infection control",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Infection control",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/35/10805\">",
"           Controversies in control measures to prevent surgical site infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/4/2121\">",
"           Antibiotic lock therapy for treatment of catheter-related bloodstream infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/35/31290\">",
"           Overview of control measures to prevent surgical site infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/23/18806\">",
"           Control measures to prevent surgical site infection following gastrointestinal procedures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/35/36406\">",
"           Epidemiology and pathogenesis of and risk factors for surgical site infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/4/27721\">",
"           Epidemiology, prevention and control of vancomycin-resistant enterococci",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/12/19658\">",
"           General principles of infection control",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/0/11268\">",
"           Infection in mesh graft following hernia repair: Clinical manifestations, diagnosis, and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/59/17338\">",
"           Prevention and control of methicillin-resistant Staphylococcus aureus in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/28/32200\">",
"           Prevention and control of varicella in hospitals",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-2083B4AA07-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f40_44_41677=[""].join("\n");
var outline_f40_44_41677=null;
var title_f40_44_41678="History physical exam A";
var content_f40_44_41678=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F76095%7EOBGYN%2F56135&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F76095%7EOBGYN%2F56135&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 517px\">",
"   <div class=\"ttl\">",
"    History and physical examination",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 497px; height: 600px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 517px\">",
"   <div class=\"ttl\">",
"    History and physical examination (cont)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 497px; height: 586px; background-image: url(data:image/gif;base64,R0lGODlh8QFKAsQAAP///wAAAIiIiERERCIiImZmZt3d3ZmZmbu7uxERETMzM+7u7lVVVczMzICAgKqqqnd3dwAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAADxAUoCAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ19AwGhAgADBSIGAQgKECICBAsHCaEDDQKhpgsMoQGsAA8BpgCoBicEuwENBKMABQoLvsAjAQQiCwnUuwa2DCLKIr+mBccBA6ABBwCqoQoNANvdy57ylaXpyPXCqQ3IBgkPCwEeAMiFTsAAEQqcpVMgolyCZ8OKoRuxr8GDBMRIDXgoIpTAA9M6InCXIAE6bxo5/4ocMWBUv2ADXgkoeTLevJuQ8JnEh2qkAAUMuAG06e7gvmckUCVDF9EEgYkjfhIQmG9px3IAFMRc6WrmAm9Kn0ob2XDUTxL+uj5EibNto3ogDZjbRZaAygPmCjwzmI5aibN8m5Ywlq0jw1YM+QIIMPOBMr+p3L1KUMAb4IMryzLD3O2AK2uVibodbWguOp6Ri5pYsEr1vowjCIcyIJiEWBIQFKCUHYDYOXECXHGlZosxAN4ZU5Mye1hEWuKiSEs/hK9hsJ6tMCOgNVCBWcwJialCEADpAAi1Y0OFZuCXAfLmWZ1r8FD4Yp9+jQmA37CX8pb5wCRTfsZNZ6Ag1ZFyXf9qihmgSyjcFGeKXKEkAEEB3IgQCyq7cHbcMQag1AyGI8SyGFTCZWMfSAKQqGECmZmDjjoBsCOZhgUeqOOOPPbo449ABinkkERO58A4SCap5JJMNunkk1BGKeWUVFZp5ZVYZqnlllx26eWXYD7pQJFklmnmmWimqeaabLbp5ptwxinnnHTWaeedeOap555qkLeLWbtkaASSCCAHSkaH+lkjbEUoqgCjUChKAFlPkJdRAaWM4+EREGQIFELFHUMpny1YStKNIYo2hGLHrQcKKxy+1xspgjY66wC1RjprblGYutlYTVw0UEkDIZMdqTKY2umNADAQzBGs3tbQRgtAkOj/rPYZYWq2vc4aVLeXcqacEgBZxAA7wh6LLAyKArOAcPStV0S0IJYyQCxxWcras7YasC8Vig4AKRPtkgNsEwwIAIHCCgvK6rqlzvrVwrvwa0S0rhYAEgOWOoqUtrsoNIWlG4IrAqYHMyHAueYqQJVqELtg6lfB+bUExiTUkwACHc+qhK9VKCuyE76inBkT9MFoTXlRbRpzCu0y8K7NStCbTXU9D9zvFb5iVanPRt/3RAKeNgfz02inrfbabLft9ttwxy333J0cGebdeOet99589+3334AH/uWYbQVA9+GLGI744oYozvjjgTgO+eR8SE752zOtc1K9xvXEYSjUzCUo/zjqaWH55Wy7QtaFreZsDG2p1FZPP1Q5hJS0V5yOutomOZVxOZ77bB0AFVV1G+5W6L7709hJ+OHVBZBnCwKfh2ROAstc1pnpy7vd+8mm4F7Pg9QLryBrvSDXehbKdw8xBN87u/7wHJbP6Owm8UcKK8hX0b7768pcjTYHvZPF7hihCwZ5CCAoE/EmdwCMYBv+J8EKfoGCFqST3QTHwQ568IMgDKEIRyg4wuEEgxlMIQRVyEIvoLCFMHTCC2NIwyTMsIZqaoACNNe6EA3AT6Hr3LjScEMcoqk17gjfAb6iQMXFpDfYYUMRjWgmrQzmJ88ij3WAN0Q0TJGKZGqAOMjRDv9jYGQEWlSQ9Lp4hi+C0UzNOM6FRJbG8YViVER8I50UMBGUieVcIqjjhO44QT3OCQIhI8ZtBuAy0CnIgHj0oiEnWQQ3UvKSLbAkJg20QRJ68pOgDKUoR0nKK5nwJprcpCpLkMpVurKVrlQlLGOJyVnS8iagcElkaGQjkIBuGWMMBToQeYuPXfCWZ3oi7KhHmYa84gB+mckoCsCvixBDh1rbgi2R6Ql7CSwVZxmBP6AZFYZQkwQXiSQYtslNTpRijQgIW6vIGUjDBfMc7tgh9sbAznZqwo7gNNs4bXaWc56APi87pj+JNLs7okJAsIhm7wzaCr0Qb2di6OdCL4EPcYz/hJft8OU0+niMA9AoR+vcqEqlsdKVarSlj+hkKWdK05ra9KY4zdIp5/FSmGawpz6tIFCDGsGhEtV9Rj0qIlBTvl1QAznvOI4rxqGqLiRVqaVZkP1ss56Z9A4laSzDVbFKCKbWBndqoVk920hWA83FoQh83mw+QxmwjhUId20rIMxqPrRCp0BhJUNe9eoHvjLKr90A7GB7sFjC7oGvTpVrb1akWLY6dpONvSzcMqvZOcg0p6ANrWhHS1oP7lQenO0s21KrWrWxtrVoey1sYybb2a6rtrYlFW5zu6fd8jZPvv3tnYIr3DoRt7hzOi5y46Tc5b6puc69wmdLS93qWve6/9hd0mk9Ad3orqm73k0TeMN7pvGSt0zmPS8U5vKoxfwpsYXJis90qDneMCYWs2jHCtX7FlzsE5+/eAbyEJAA7yCkFy1aa7EEQhAspJe/TcBfO/A5k+2RAEP0tGIJ0jgULjwYwktgLzpCVhcQWeMfGBVjfhUMALwU08EgZgQ+bAGQAyDUwjiqWAniaI/VIDF5MV7EjB8C4ASU0VW9gA8fT6YdxW2nHaypKhQ+HOQjzEUs+JRMiEBkLHgQc1EKdlCg2Ffl7lG5zAc6M5p/MN3suvnNcI5zKLfbCTWvmTR2vrNb8qznE/Z5EBQN6zlzmY+RHGCH0xgFfQco2D8LItCOG//063oivWMhMcH8dHQgID2CQWPqmwiQXwk0bAY+a/oGnAafGhmTCm8AkXhj5E6mT+2HVDeLFQAN9bPo2WmzpZTWfaBoh+P1yPr9AsHUWPKvZg3sPdwTAfjlxfCYEZlD/xIAX24vs5sdN1Nz+xLe/nYlwi1uFbRZzuhOt7rXDSY6c4Lc5Y4EvOP9iHnTuxH2vnfi9L1afq8t3/4+BMADXoiBE3wQBj945BROW4ZDLOEO7wPExX1udlv84hjP+DHcvYmJR1wPHv84HkIucjuQvOR0ODm3IetIaDzrGAIQ6S7EivIzGLYEtusIOgKsmVLX3Aw3H0FYJkJhGPWc5j8nw1v/DxhZ7bm3RpQCkM+TPoagw3c2J7rx0RtNdTFYXX/nOZEvjLz1bXfdCyyfhotaDKMsu4IYUkf62eWk8rmroe6arrjG9873vluX45rAu90tO/jnFh5Ogj+82RUvXsa3KfGOV2jkGz95yle+vJdHE+QzT2bOo9fznwd9E/Tu99Kb/vSkBHwmNi96KrC+9VJ4PeynPHshyb72Tbg97peg+93b0Pc+6j3wBzV8Hgm/+EM4PvKDoPzl/6D56iU96qdP/eoHTvWYgL7zeaD97eug+97HAfjDb4Pxk58G5j+/DNKvfhiwv/0ueD/8WSD/+aug/vZHAf7zb4L9858E/mdb0md9/wRYgAa4JdgHbv/3bgvYcQ0YeA+4ehE4AwBhM8eQIbLBABkBUu7gdvhkKEKkTkwQgL/1ExglduRxZMIQEwvwEs70LjWSWCfhKpPGRiM4gTKgDAYFYK8wP2khUA/gCpPyAKAwgznzaVEUBSSYW/BBYM9wgSpYFvL0FF2BYR9YL9HDaiLIezgIA/c0YhMBSNLyg2gRhASACm1nhCxhCuQzBUs4WyeGGGLXLAchFnJBDQ/1gsKRMGInPoNkg1zYhS1gIqeADMdgIxmIFBzILVdYQNS2hUrwhvknifZHiZo1gAeYiZq4iUqSgJZgifAHiu0niupHiudniuSHiuGnit7Hiv/b54rOB4vLJ4vIR4vFZ4vDh4sthYmc2Iu+WICeOG6CSAm66HvFuHvHiHvJWHvLOHvNCHvP2HrRKHrTCHrV6HnXyHnZmHnbuEq8+IvgGI5+F4zEOIyT0I2Vh46Tp46Rx46O546MB4+KJ4+HR4+FZ4+Dh492p49zx49n54849I3iOJAEuW7keI7mKAkASXULmXQN+XMPWXMRiXITWXIVKXIX+XEZGXEb6XAdyXAfqXAhGUECWZAmeZLYdZAKmZDyxpKQMJIEB5MBJ5MRNBfTVFK8ZmAnwwAyQjyIxhZ/cQvuFVLngCShom0CJDWkIEyEEmmmEG2yRpMAVA8pSFEtRlD/fhGHAOKC7pArJKAY00ANIMES2eMXrfELTPEpy0GWLEZNAMFgDEB0LpkCOnEAVslrAGFoRgcg4fSVpwOW0jSWPSccasUAvUA8TBN3UidoeoFSHTGXKAAXvfGFvHZra7mWmOaXJgCWnsFqbNmBQilVQncr8bCYTtlieYEUUuk+psEM/FKZ1uQzfEk1KsCZXxEKnykcPGaYFJGYpbkMYcWbI4A+jwmZJpAgd0mbBcYZW0k2rRAhf4kZ+ORLuWmWT4lPBqCWirkMw5Y/3BFlxWmcR3hhOAlz2JZlPclLgBKU0ZBlxlCdp2AZshAAStmTl8l2oQArD0KfLCWeirCa9wag/5dTkihZoAYKWirZkv6ZCAIabw1abg9KOReBFEpxnlDRAHOhFzISVShBOr+2oADwPWdhDV5jDRmiCnBnFjQhmilhTB4GoiJgLfDAdhHBLWyZVmCBDLdBHpCohDCKmAvghPuzlkZTGLMJGpaRGE3Wo7T3o95xTtVDHDYTEbMJmqOgPi70o5KBUeF0Yv0wAM/wGphJIPvBNEPKo9qkpRU4oztJPBm6ABvqFyyydiaCptyjpYQQod+mp4xDoAf6p4A6Sgn6kniap4WKcIcqCHzabIsKOaGigV94lP6iHMqQDTz5IvqVpTAKAQTQDnIRT/xiH60havwRGTRDO2HQqIzjD/87FqrUoFYTygwZkhoEFnbTYlU/aj7UtgudGZohimJk8R9mqhG4CqPf02muygzN0Sm8lhoXgSsZ9aOcOhKfapWiGgz7oJNi0w8HwK23+qI/GkwFYACR6hepghA+czUZEgvt4DVpmqiAoKqnJq9z46eBeq/4CkKDWm/wGq/9+gf06mgBSzdShwoyNxtxZZ5ic5U+yUPFCqIFK5vLUBsAxjSpQU6XZjGdB7ETK7GFyChFlxkY6zSO6T8/GrGI0rGRRWIiSw0qRkYdIWU+CqNSdxQ9R7E2xqoL25cn42sbu6CcSgyV8Zk4O3btYEX/omxFKrNNCqJwug6ZGrErOxFvt2j/YHqe65AcTPsEA9tnXatnX3tnYds29pqvZnu2fbOvjjC2aMa2Zea2VQa3QSa3bLOmV6eB9tCDKPOFl8p2+rVD2QRkP2qCdcEULLhA4XAQVnmqOktg2vquMKqDwTCGD0AeIBFPimsxtXqYGGaBW5t7P9qEHCEtLWEpMbG3JdUQZnpi1hCsn3uDMPqFPli5vbEPBmOVYwetLXYMGrtf/hmH+dRDW2Eq4pC5SWES3mqrpfq6gbighGg8gfIMpoIKiltSusuuXSaaJeuG/+oHdAti3xszZYu25Fu+XqK2+Na9Eqe+lcO+exC+/AW/6iW/50W/5GW/4YW/3qW/0cW/zuW//8sFwMglwHYyvuZ7wAhMJejLCAQsXA38Ww/MWxGcWxNMJ6JjQLx6lZqDJC5XOitgbYl2mcNgn4h0oT/JvPp3shPCqlaJliezDIpJLTiGApWmGih7mSSKGVy5MjdQwXNSD8VjlcKJcx1rFfNDrCQgajnTsSn6IjXqs+V3shUCTNYrL4OppDPsrjP6ajcsdWHHl71bAz4sJ6VAnK6ZxL0rderTPyWgxORUs76ZD01Hmz2swsIwUdVUIAUAw6MAdvzjKptybK1ADUHLDH7Bl4fhpc7ZlXVMs00UT6krQD+kGXQKIw+kxRpywgNhDjYiI2xBIurZyO47cqOcB2PsJgacwP+qvMqduGelTMqvbHKxLMuznHK1bMu3LAenrFq73Fm9rFm/fFnB7FjDTFjFrFfHbCapzMrMzMoLvG+5HAfJTFbTjFXVrFTXfFTZTFTbHFTd7FPfDFPh3FLj7FLRLM3nDAfl3CPL3MzufMDP/J/p/AbrvFH1vFD37E/53E77zE39jEz/fEsBTUsDHUsF/Urz7AYHvUoLjRPt/M4QfbbxzKAJXUgVvQYNjVkXjdEbfXcdnUcfTXghzXUjTdIlHa0nvXgp/bArLXnG+dARHdOBOtGIkNG11NKpitMfqtPgytM97dN3CtRBLdQwRtQ/a9Qmi9S+q9Tcy9RJ7dRNLZ4wLdP/VF2gNC1wUO16WR3VW821XT2zXy1DYe3VYw26ZQ27Zx2Jad28a30ENn1Jb01JcV03VV3XEX3VjdPWv6fXbs3Xfe3XlQTYgS3YyUfYhW3YzIfYia3Yz8fYje3YjAXZke2fU23Xlg2OeF1wks19m70Dc21In61Hof1Gow1GpU1Fp21EqY1Dq11DrU1Drx1DsQ1Dsx0JlX3ZuL2JmW2onZ0Dtc1Cv61CwZ1Cw/1Tve3bxy1+yS3Kyz0DxW1Bzy1UzS3G041+C3rbuZ3dwOjK1b1+3e3d3+1+4S3e4x1/5W3e501/6a3e631/7e3e753C8X0C0S1B9Z0I2K3d+j19u42oP/Pdf/8N4AEOgANO4AUengV+3wCk4Eh14Ag+4AxuZg6+GBMe4YWQ3/ud4eM44Rze4R7+4SAe4iI+4iRe4pAdAgA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_44_41678=[""].join("\n");
var outline_f40_44_41678=null;
var title_f40_44_41679="3-D ultrasound of club foot";
var content_f40_44_41679=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F78391&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F78391&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    3-dimensional ultrasound picture of a club foot",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 345px; height: 438px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Rendered 3-dimensional image of a second trimester fetus. the lower legs are demonstrated. Both feet are abnormally positioned with the plane of the lower legs parallel to that of the sole of the foot. A fetus with the feet persistently in this position has bilateral talipes equinovarus, or bilateral clubfoot.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Shipp, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_44_41679=[""].join("\n");
var outline_f40_44_41679=null;
